WO2021000844A1 - Device and method for delivering exogenous substances into eukaryotic cells and application thereof - Google Patents

Device and method for delivering exogenous substances into eukaryotic cells and application thereof Download PDF

Info

Publication number
WO2021000844A1
WO2021000844A1 PCT/CN2020/099054 CN2020099054W WO2021000844A1 WO 2021000844 A1 WO2021000844 A1 WO 2021000844A1 CN 2020099054 W CN2020099054 W CN 2020099054W WO 2021000844 A1 WO2021000844 A1 WO 2021000844A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
piston
eukaryotic
unit
Prior art date
Application number
PCT/CN2020/099054
Other languages
French (fr)
Chinese (zh)
Inventor
陈汉
刘玲蓉
杜博
Original Assignee
广州世赛生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州世赛生物科技有限公司 filed Critical 广州世赛生物科技有限公司
Publication of WO2021000844A1 publication Critical patent/WO2021000844A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/04Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Definitions

  • the present disclosure relates to the field of biotechnology, in particular to a device and method for delivering exogenous substances into eukaryotic cells and their applications.
  • Cytoplasmic and nuclear delivery are key steps in cell engineering, cell therapy research and development, and many biological functions.
  • Existing conventional intracellular delivery technologies include electroporation, viral vectors, or non-viral gene vectors.
  • electroporation often leads to higher cell mortality; viral vectors are immunogenic, and the construction of viral vectors that deliver specific sequence nucleic acids takes a long time and is low in efficiency; non-viral gene vectors have low delivery efficiency in suspension cells and primary cells. It takes a long time and is not suitable for delivering other biological macromolecules except deoxyribonucleic acid DNA and ribonucleic acid RNA (Stewart M P, Sharei A, Ding X, et al.
  • the prior art also has a porous membrane-based macromolecule delivery system that can deliver microcircle DNA to the nucleus of artificial hematopoietic stem cells (WO2018064387A1, CN201780060638.6) and express the GFP gene.
  • this delivery system has the following drawbacks: the single-channel device has a small processing volume of cell suspension (only 50 ⁇ L), high cell density in the suspension (up to -10 7 cells/ml) and the resulting low cell recovery rate (12% to 57%), and minicircle DNA (the number of base pairs is about 0.7kbp) transfection efficiency is extremely low (1% to 8.4%).
  • this disclosure has designed a device with a temperature control module, and conducted various macromolecule delivery and plasmid DNA transfection experiments.
  • the present disclosure provides a device for delivering exogenous substances into eukaryotic cells.
  • the device alleviates the deficiencies of the existing eukaryotic intracellular delivery technology, such as the inability to rupture and perforate the nuclear membrane of the cell.
  • a combination is required
  • Microfluidics and electric fields, as well as carrier-based intracellular delivery methods are only suitable for technical problems such as the delivery of specific molecules such as nucleic acids.
  • the present disclosure provides a device for delivering exogenous substances into eukaryotic cells.
  • This device can process a higher cell suspension volume and reduce cell density in a single delivery test, thereby obtaining better cell recovery and survival rates .
  • the present disclosure provides a device with a temperature control module, which can achieve higher delivery efficiency and higher cell recovery rate by changing the delivery temperature.
  • the present disclosure also provides a method for delivering exogenous substances into eukaryotic cells, the method comprising extruding a mixture of eukaryotic cells and exogenous substances through the device of the present disclosure.
  • the present disclosure provides an application of a high-throughput eukaryotic intracellular delivery device or a method for delivering exogenous substances into eukaryotic cells in regulating cell functions.
  • the present disclosure provides a device for delivering exogenous substances into eukaryotic cells.
  • the device includes an extrusion module in which a microporous membrane with regular pores is arranged, and the pore diameter of the pores is smaller than that of the true cell.
  • the diameter of the nuclear cell also includes a pressure unit for driving eukaryotic cells and exogenous substances through the pores at the same time; in one or more embodiments, the pressure unit includes a piston unit or a compressed gas drive unit.
  • the device further includes a temperature control module for controlling the environmental temperature of the extrusion module and the cell suspension system.
  • the present disclosure also provides a method for delivering exogenous substances into eukaryotic cells, the method comprising: extruding a suspension system containing eukaryotic cells and exogenous substances through the above-mentioned device, so that the exogenous substances are delivered to the eukaryotic cells.
  • Nuclear cell
  • the present disclosure also provides the application of the above-mentioned high-throughput eukaryotic intracellular delivery device, or the above-mentioned method of delivering exogenous substances into eukaryotic cells, in regulating cell functions.
  • the beneficial effects of the present disclosure include at least:
  • the device for delivering exogenous substances into eukaryotic cells is provided with an extrusion module in which a microporous membrane with regular pores is arranged, and the pore diameter of the pores is smaller than the diameter of the eukaryotic cell;
  • the output module also includes a piston unit for driving eukaryotic cells and exogenous substances through the pores at the same time;
  • the device also includes a temperature control module for controlling the environmental temperature of the extrusion module and the cell suspension system.
  • the cells suspended in the solution can be compressed and deformed in the process of passing through the pores, thereby causing the cell membrane and nuclear membrane to perforate, so that the exogenous materials dispersed or dissolved in the cell suspension enter the cytoplasm and nucleus.
  • the eukaryotic intracellular delivery method provided by the present disclosure overcomes the shortcomings of the existing intracellular delivery technology, such as the intracellular delivery technology based on nuclear pore membrane.
  • the cell processing volume is too small (50 ⁇ L) and the cell density is too high (up to -10 7 cells).
  • minicircle DNA transfection efficiency is extremely low (1% to 8.4%), and the cell recovery rate (12% to 57%) of minicircle DNA delivery is low, such as intracellular delivery based on microfluidics Technology cannot rupture and perforate the nuclear membrane of the cell; or in order to deliver plasmid DNA into the nucleus, a combination of microfluidics and electric fields are required, and intracellular delivery methods based on non-viral gene vectors are only suitable for the delivery of specific molecules such as nucleic acids.
  • the device for delivering exogenous substances into eukaryotic cells can not only deliver exogenous substances of various molecular weights into the cytoplasm, but also deliver a hydration radius larger than the upper limit of the diffusion of the nuclear pore complex (NPC) Exogenous substances, such as 2MDa FITC-dextran, are delivered into the nucleus with high efficiency. Therefore, it is shown that the present disclosure achieves cytoplasmic and nuclear delivery by simultaneously inducing rupture and perforation of cell membrane and nuclear membrane. Secondly, the device provided by the present disclosure can efficiently deliver plasmid DNA with a larger hydration radius into the cell nucleus and express the encoded protein.
  • NPC nuclear pore complex
  • the present disclosure can deliver various types of exogenous materials into the cytoplasm and nucleus without being restricted by the physical and chemical properties of the materials themselves, such as dextran and plasmid DNA.
  • the present disclosure does not require electric field assistance when delivering plasmid DNA into the nucleus and expressing the corresponding protein.
  • the device provided by the present disclosure is suitable for high-throughput cell-containing system through the microporous membrane, a single treatment of cell-containing suspension can reach at least 0.5 mL, and the total number of cells extruded at one time can reach at least 0.6 ⁇ 10 6 pcs.
  • the present disclosure also provides a method for delivering exogenous substances into eukaryotic cells, the method comprising extruding a mixture of eukaryotic cells and exogenous substances through the aforementioned device. Therefore, it has all the beneficial effects of the above device, which will not be repeated here.
  • Figure 1 is a schematic diagram of the principle of a device for delivering foreign substances into eukaryotic cells provided by the present disclosure
  • FIG. 2A is a polyethylene terephthalate (PET) nuclear porous membrane used in Examples 1-3 of the present disclosure
  • Figure 2B shows the pores on the PET nuclear porous membrane used in Examples 1-3 of the present disclosure
  • 2C is a device for delivering exogenous substances into eukaryotic cells provided in Example 1 of the present disclosure
  • Fig. 3 is a device for delivering exogenous substances into eukaryotic cells provided in Example 2 of the disclosure
  • Example 4 is a device for delivering exogenous substances into eukaryotic cells provided in Example 3 of the disclosure
  • 5A is a confocal picture of 70kDa glucan delivered to CT26 cytoplasm and nucleus in Example 4 of the disclosure;
  • Figure 5B is a confocal picture of 2MDa glucan delivered to CT26 cytoplasm and nucleus in Example 4 of the disclosure;
  • 6A is the flow cytometry data of the delivery efficiency of 70kDa glucan to CT26 cells in Example 4 of the disclosure
  • 6B is the flow cytometry data of the delivery efficiency of 2MDa glucan to CT26 cells in Example 4 of the disclosure
  • Figure 7A is the flow cytometric data of the delivery efficiency of 70kDa glucan to K562 cells in Example 5 of the disclosure
  • Example 7B is the flow cytometry data of the delivery efficiency of 2MDa glucan to K562 cells in Example 5 of the disclosure.
  • Figure 8 is a confocal picture of pCMV-GFP plasmid delivered to K562 cell nucleus and expressing GFP protein in Example 6 of the disclosure;
  • Figure 9 is the flow cytometry data of pCMV-GFP plasmid delivered to K562 cell nucleus and expressing GFP protein in Example 6 of the disclosure;
  • Figure 10 is the flow cytometry data of pCMV-GFP plasmid delivered to CT26 cell nucleus and expressing GFP protein in Example 7 of the disclosure;
  • Figure 11 is a confocal picture of the delivery of 2MDa glucan to K562 cytoplasm and nucleus provided in Example 8 of the disclosure;
  • Figure 12 is the flow cytometric data of 2MDa glucan delivered to CT26 cells provided in Example 9 of the disclosure.
  • FIG. 13 is the cell recovery rate after extrusion treatment of the CT26 suspension with different density provided in Example 10 of the disclosure.
  • Figure 14 shows the intracellular delivery efficiency of K562 cells with different molecular weight exogenous substances provided in Example 11 of the disclosure under the same pore size nuclear pore membrane condition;
  • 15A shows the delivery efficiency and cell recovery rate of 2MDa FITC-dextram in CT26 cells at different temperatures provided in Example 12 of the disclosure
  • 15B shows the transfection efficiency of pDNA in CT26 cells at different temperatures provided in Example 12 of the disclosure
  • the present disclosure provides a device for delivering exogenous substances into eukaryotic cells.
  • the device includes an extrusion module in which a microporous membrane with regular pores is arranged, and the pore diameter of the pores is smaller than that of the true cell.
  • Nuclear cell diameter; the extrusion module also includes a piston unit for driving eukaryotic cells and foreign substances through the pores at the same time.
  • the extrusion module is driven by the piston unit to deform the cells during the process of passing through the pores, thereby causing the cell membrane and the nuclear membrane to perforate and increase the permeability, so that the foreign substances scattered around the cell enter the cell and the nucleus.
  • Regular pores refer to the uniform shape of the pores on the microporous membrane, which are round or nearly round. Since the device for delivering exogenous substances into cells provided in the present disclosure is suitable for the passage of higher flux cells, since the number of cells passing through the extruded membrane each time is large, if the pores on the microporous membrane are irregular, the cross-section There is a greater difference in shape, the cell death rate will be higher.
  • the "cell” described in the present disclosure also refers to "eukaryotic cells”. It can be understood that the device also includes a storage space before the cells and foreign substances pass through the microporous membrane, and a receiving space for receiving the extrudate after extrusion.
  • the present disclosure does not limit the shape, volume and material of the storage space and the receiving space, as well as the connection mode of the storage space, the microporous membrane and the receiving space, as long as the cells and foreign substances can pass from the storage space through the microporous membrane, and from The flow between the microporous membrane and the receiving space is sufficient. It is understandable that the device can be used independently or in conjunction with other devices to form a system.
  • the temperature of the extrusion module is 28-31°C, such as 28-30°C, such as 30°C. In one or more embodiments, the temperature of the extrusion module is, for example, 28.2°C, 28.4°C, 28.6°C, 28.8°C, 29°C, 29.2°C, 29.4°C, 29.6°C, 29.8°C, or 30°C.
  • the eukaryotic cell concentration in the suspension system containing eukaryotic cells and exogenous substances is 1 ⁇ 10 6 cells/ml to 4 ⁇ 10 6 cells/ml, for example, 1 ⁇ 10 6 cells/ml. 10 6 cells/ml to 2 ⁇ 10 6 cells/ml.
  • the eukaryotic cell concentration in the suspension system containing eukaryotic cells and exogenous substances is 1.2 ⁇ 10 6 cells/ml, 1.4 ⁇ 10 6 cells/ml, 1.6 ⁇ 10 6 cells/ml, 1.8 ⁇ 10 6 cells/ml, 2.0 ⁇ 10 6 cells/ml, 2.2 ⁇ 10 6 cells/ml, 2.4 ⁇ 10 6 cells/ml, 2.6 ⁇ 10 6 cells/ml , 2.8 ⁇ 10 6 cells/ml, 3.0 ⁇ 10 6 cells/ml, 3.2 ⁇ 10 6 cells/ml, 3.4 ⁇ 10 6 cells/ml, 3.6 ⁇ 10 6 cells/ml, 3.8 ⁇ 10 6 Cells/ml or 4.0 ⁇ 10 6 cells/ml.
  • the material of the microporous membrane includes metal or non-metal. In one or more embodiments, the material of the microporous membrane includes non-metal, and the non-metal includes, but is not limited to, polymer, ceramic, or silicon.
  • the material of the microporous membrane is polymer.
  • the microporous membrane prepared by using the polymer as the substrate has uniform pore distribution, and the microporous membrane is lighter and thinner.
  • the polymer includes but is not limited to polyethylene terephthalate, polytetrafluoroethylene, polycarbonate, polyimide, polyamide, cellulose acetate, nitrocellulose, polyethylene, polyethersulfone or Polytetrafluoroethylene; for example, polyethylene terephthalate or polyimide or polycarbonate.
  • the polymer is selected from polyethylene terephthalate, polytetrafluoroethylene, polycarbonate, polyimide, polyamide, cellulose acetate, nitrocellulose, polyethylene, polyethersulfone, and polyethersulfone. At least one of the group consisting of tetrafluoroethylene.
  • the method for preparing the pores on the microporous film includes etching or perforating.
  • the etching is preferably track etching or photoetching, and the photoetching is preferably laser etching; and punching is preferably used for perforating.
  • the microporous film is prepared by track etching, which has better effect.
  • nuclear pore membrane is also called “nuclear track membrane” or “nuclear track-etch membrane”, which generally refers to radiation track-chemical engraving Non-metallic film obtained by etching technology.
  • Nuclear porous membranes have unique microporous characteristics and uniform pore size, and are widely used in the field of membrane separation.
  • the microporous membrane is a nuclear porous membrane.
  • the piston unit applies positive pressure to the cells and exogenous substances, and the piston unit may be manually driven by hand or driven by a driving unit. In one or more embodiments, it can also be driven by compressed gas.
  • the piston unit includes a piston tube and a piston push rod.
  • the piston unit includes a driving unit for driving the piston push rod, and the driving unit can select a conventional unit capable of providing power, for example, using a motor to drive the piston to move, so as to apply cells and foreign substances. Positive pressure towards the microporous membrane.
  • the material of the piston tube body includes metal materials, alloy materials, or non-metallic materials other than glass; in one or more embodiments, the metal material includes aluminum or copper; In various embodiments, the alloy material includes stainless steel or titanium-magnesium alloy.
  • the piston push rod is mainly made of natural polymer materials or synthetic polymer materials.
  • the natural polymer material is rubber.
  • the synthetic polymer material is polyester.
  • the synthetic polymer material is polytetrafluoroethylene and/or polyethylene.
  • a polyethylene terephthalate material is used to prepare the piston push rod.
  • a piston unit composed of polyethylene or polytetrafluoroethylene is used; in one or more embodiments, a piston unit made of polyethylene is selected. Synthetic polymer materials have good mechanical strength, corrosion resistance and smooth surface, especially polyester, polyethylene and polytetrafluoroethylene.
  • the device further includes a temperature control module, which is used to provide a constant temperature to the extrusion module, so that cells and foreign substances can be extruded under a specified temperature condition.
  • the temperature control module is in contact with the extrusion module, so that the temperature is more directly transferred to the extrusion module to control the temperature of the extrusion module.
  • heating metal wires, ceramic heaters, semiconductor refrigeration fins or fluid circulation temperature control units are arranged on the outer wall of the space for storing cells and exogenous substances in the extrusion module.
  • the fluid circulation temperature control unit is provided with a cavity in contact with the extrusion module, and the cavity is used for fluid circulation in the fluid circulation temperature control unit.
  • the device further includes a temperature control module configured to control the eukaryotic cells and exogenous substances in the form of the extrusion module and the suspension by contacting the extrusion module temperature.
  • the temperature control module includes a fluid circulation temperature control unit or a semiconductor refrigeration unit.
  • the fluid circulation temperature control unit is provided with a cavity in contact with the extrusion module, and the cavity is configured for fluid circulation in the fluid circulation temperature control unit.
  • the pressure unit is a piston unit, and the piston unit is configured to drive eukaryotic cells and foreign substances in a suspension form through the pores at the same time.
  • the piston unit is configured to apply a positive pressure to the cells and the foreign substance, so that the cells and the foreign substance pass through the pores.
  • the piston unit includes a piston tube and a piston push rod.
  • the piston unit includes a driving unit for driving the piston push rod.
  • the microporous membrane is detachably connected to the piston tube body.
  • the material of the piston tube body includes metal materials, alloy materials or non-metal materials other than glass.
  • the non-metallic material other than glass includes plastic.
  • the non-metallic materials other than glass include polymer materials.
  • the material of the piston push rod includes natural polymer materials or synthetic polymer materials.
  • the present disclosure also provides a method for delivering exogenous substances into eukaryotic cells, the method comprising extruding a suspension system of eukaryotic cells and exogenous substances through the above-mentioned device.
  • the suspension system described in the present disclosure refers to a system in which eukaryotic cells and exogenous substances are dispersed.
  • the dispersion medium of the system can be a conventional medium that can maintain the activity of eukaryotic cells, including but not limited to medium, physiological Saline and PBS buffer, etc.
  • the delivery described in the present disclosure refers to the introduction of foreign substances into cells, that is, foreign substances into the cytoplasm, or foreign substances into the cytoplasm and nucleus.
  • the method for delivering exogenous substances into eukaryotic cells provided in the present disclosure can be performed at room temperature, and the room temperature described in the present disclosure refers to an ambient temperature without human intervention.
  • the temperature of the extrusion module is similar to the ambient temperature.
  • the exogenous substance is delivered into eukaryotic cells at a preset temperature.
  • Delivering exogenous substances into eukaryotic cells at a preset temperature has higher delivery efficiency, cell recovery rate and survival rate. Therefore, the method of delivering the exogenous substance into eukaryotic cells is performed at a preset temperature.
  • the preset temperature is regulated by the temperature control module of the device for delivering the exogenous substance into the eukaryotic cells.
  • the suspension system containing cells and exogenous substances is extruded through the device at one time; wherein extruding through the device at one time refers to applying continuous pressure to the mixture to make the mixture Uninterrupted through the microporous membrane.
  • the volume of the suspension system extruded through the device at one time is at least 0.5 mL.
  • the number of cells in the mixture passing through the microporous membrane in a single pass is at least 0.6 ⁇ 10 6 cells.
  • the method can process cells with a larger flux, and has the advantages of a single cell suspension treatment volume (>0.5 ml) and a single treatment cell throughput (>0.6 ⁇ 10 6 cells).
  • the incubation is continued for a period of time, the cell membrane pores and nuclear membrane pores are repaired after the incubation, and the exogenous materials can be retained in the cytoplasm and nucleus.
  • the method further includes separating the exogenous substances in the suspension system before continuing to culture the extruded cells, optionally using a centrifugal method to remove the exogenous substances, and then removing the exogenous substances Continue to cultivate.
  • the present disclosure does not limit the types of foreign substances, and those skilled in the art can use the methods of the present disclosure to deliver any foreign substances into any cell according to actual production and research needs. And based on the beneficial effects of the device for delivering foreign substances into cells provided by the present disclosure, the method of the present disclosure is particularly suitable for delivering larger molecules into the cytoplasm and nucleus.
  • exogenous substances described in the present disclosure may be natural substances, including but not limited to nucleic acids, proteins or glycoproteins from natural sources; they may also be artificially synthesized or modified substances, including but not limited to macromolecular polymers , Artificial synthesis of nucleic acids or nano-components, etc.
  • the exogenous substance can also be modified by a modifier, including but not limited to the use of fluorescent labels, isotope labels or drug modifiers; in one or more embodiments, the exogenous substance includes nucleic acids modified by fluorescent labels, Isotope-labeled protein or drug modifier modified synthetic macromolecules with therapeutic effects, etc.
  • the foreign substance can be a single kind of substance or a combination of different kinds of substances, which preferably includes one of dextran, DNA, RNA, protein, ribonucleoprotein complex and nanodevice. Species, or a combination of several.
  • foreign substances include a mixture of DNA and ribonucleoprotein complexes.
  • foreign substances include a mixture of DNA and protein.
  • the foreign substance includes a combination of dextran, DNA, and nanodevices.
  • DNA includes biologically derived DNA or synthetic DNA.
  • the biologically derived DNA includes DNA molecules amplified by biosynthesis, including but not limited to plasmids extracted from microorganisms or DNA molecules directly extracted from microorganisms or animals.
  • synthetic DNA refers to a DNA molecule synthesized without biological action, for example, a DNA molecule synthesized directly chemically.
  • the biologically derived DNA includes a plasmid to transform the plasmid with the target gene into the cell, up-regulate or inhibit the expression of the target protein, or allow the cell to express an exogenous protein.
  • RNA includes mRNA, siRNA, miRNA, or lncRNA to study the regulatory effect of RNA-based molecules on eukaryotic cells.
  • the device for delivering exogenous substances into eukaryotic cells provided in the present disclosure can deliver exogenous substances with a hydration radius larger than the upper limit of the diffusion of the nuclear pore complex (NPC) into the nucleus. Therefore, in one or more embodiments, at least one of the exogenous substances cannot cross the nuclear membrane nuclear pore complex of the cell nuclear membrane by free diffusion.
  • NPC nuclear pore complex
  • the substance that cannot cross the nuclear membrane nuclear pore complex by free diffusion includes dextran, and the molecular weight of the dextran is at least 41kDa, for example 70kDa-2MDa, such as 2MDa dextran. Glycans.
  • the substance that cannot cross the nuclear membrane nuclear pore complex by free diffusion includes DNA, and the molecular weight of the DNA is at least 1 kbp.
  • the present disclosure does not limit the types of eukaryotic cells to which exogenous substances are delivered, and exogenous substances can be delivered to eukaryotic cells according to actual development and production needs.
  • the eukaryotic cells to which the exogenous substance is delivered are, for example, derived from mammals, including but not limited to humans, pigs, cows, monkeys, mice, or sheep, such as humans or mice.
  • the eukaryotic cells include primary cells or cell lines.
  • Primary cells refer to cells isolated directly from organisms, including but not limited to cells isolated from various tissues and organs of animals such as blood, skin, bones, heart or tendons, and may also include these primary cells Passage cells that have not yet constituted a stable cell line.
  • Cell lines refer to passage cells with a stable shape. These passage cells can be obtained from primary cells after stable passage, or they can be derived from commercial cell lines, including but not limited to CHO cells, PK15 cells, Hela cells, K562 Cells or CT26 cells.
  • the types of primary cells include, but are not limited to, stem cells, immune cells, tumor cells, fibroblasts, skin cells, or neurons, for example, immune cells, tumor cells, or stem cells.
  • immune cells include T cells, B cells, DC cells, NK cells, monocytes, mast cells, eosinophils, basophils, neutrophils, or giant cells. Phages.
  • the stem cells include hematopoietic stem cells, mesenchymal stem cells, or skin stem cells.
  • the immune cells, tumor cells or stem cells are derived from mammals, such as humans or mice.
  • the immune cells are human immune cells, which are more suitable for routine production and scientific research needs.
  • the present disclosure also provides the application of the above-mentioned device or the above-mentioned method in regulating cell function.
  • the present disclosure up-regulates or down-regulates the expression of certain proteins by eukaryotic cells by delivering exogenous substances to eukaryotic cells, or allows eukaryotic cells to express foreign proteins.
  • the regulation described in the present disclosure can be transient regulation, even if the cells are relatively Changing physiological and biochemical characteristics in a short period of time can also be continuous regulation, even if cells continue to change physiological and biochemical characteristics.
  • the regulation of cellular functions includes transient regulation or continuous regulation.
  • the regulating cell function includes down-regulating or up-regulating the expression of a specific protein in the cell.
  • down-regulating the expression of a specific protein in a cell includes down-regulating the expression of programmed death receptor-1, T cell receptor or major histocompatibility complex.
  • the regulation of cell functions includes allowing cells to express foreign proteins.
  • the foreign protein includes a chimeric antigen receptor, a T cell receptor that recognizes a specific antigen, and beta globulin. Up-regulation, down-regulation, or expression of foreign proteins by eukaryotic cells can be used to produce protein drugs, such as monoclonal antibodies, fusion proteins, or antigens for vaccines.
  • This embodiment provides a device for delivering exogenous substances into eukaryotic cells.
  • the device uses PET nuclear porous membrane (purchased from the Institute of Modern Physics, Chinese Academy of Sciences (Jiang Bitou)) as the microporous membrane.
  • the PET nuclear pore membrane is a PET film that is irradiated with high-energy heavy ions to form a cylindrical pipe with a diameter of about 10 nm, and then chemically etched to produce a larger specific diameter pore; provided by liposome extruder LF1 (Canada AVESTIN Company)
  • the positive pressure pressure unit puts the PET nuclear pore membrane in the liposome extruder to assemble the device for delivering exogenous substances into eukaryotic cells according to the embodiment.
  • the PET nuclear porous membrane is shown in Figure 2A and Figure 2B, and the liposome extruder LF1 is shown in Figure 2C.
  • This embodiment provides a device for delivering exogenous substances into eukaryotic cells, as shown in FIG. 3, where icon 110 is a microporous membrane, 120 is a piston tube body, and 130 is a piston push rod.
  • the device uses PET nuclear porous membrane (purchased from the Institute of Modern Physics, Chinese Academy of Sciences (Jiang Bitou)) as the microporous membrane 110.
  • the extrusion module of the device uses a piston unit as a pressure unit to apply positive pressure to eukaryotic cells and exogenous substances.
  • the specific structure is as follows:
  • the piston unit includes a piston tube body 120 and a piston push rod 130, the piston tube body 120 and the piston push rod 130 are detachably connected by sliding and sealing; a detachable piston tube body 120 is provided at the bottom of the piston tube body 120 that is far from the piston push rod 130 and enters one end.
  • the PET nuclear porous film serves as the microporous film 110.
  • This embodiment provides a device for delivering exogenous substances into eukaryotic cells, as shown in Figure 4, where icon 110 is a microporous membrane, 120 is a piston tube, 130 is a piston push rod, and 210 is a cavity. 221 is the inflow passage, and 222 is the outflow passage.
  • the device uses PET nuclear porous membrane (purchased from the Institute of Modern Physics, Chinese Academy of Sciences (Jiang Bitou)) as the microporous membrane 110.
  • the extrusion module of the device uses a piston unit as a pressure unit to apply positive pressure to eukaryotic cells and exogenous substances.
  • the device uses a temperature control module including a fluid circulation temperature control unit to control the temperature, and the specific structure is as follows:
  • the piston unit includes a piston tube body 120 and a piston push rod 130, the piston tube body 120 and the piston push rod 130 are detachably connected by sliding and sealing; a detachable piston tube body 120 is provided at the bottom of the piston tube body 120 that is far from the piston push rod 130 and enters one end.
  • the PET nuclear porous film serves as the microporous film 110.
  • the outer wall of the piston tube 120 is provided with a cavity 210, which is used for fluid circulation in the fluid circulation temperature control unit, and the outer wall of the cavity 210 is provided with passages for fluid to enter and flow out. In this way, the passage close to one end of the microporous membrane 110 is the inflow passage 221, and the passage close to the entry end of the piston push rod 130 is the outflow passage 222.
  • the two passages on the cavity 210 are connected with the outer circulation of the constant temperature water bath, so that the liquid with a constant temperature can flow in and out of the cavity 210 continuously and stably.
  • 70kDa and 2MDa glucan were delivered to the cytoplasm and nucleus of CT26 (mouse colon cancer cell line).
  • This embodiment uses the device provided in Embodiment 1.
  • 70kDa or 2MDa FITC-labeled dextran FITC-dextran, hereinafter referred to as dextran
  • dextran FITC-dextran
  • the cell suspension was passed through PET nuclear pore membranes with different pore diameter channels, and the results of intranuclear delivery and intracellular delivery efficiency were evaluated by confocal microscope and flow cytometry.
  • the test materials are shown in Table 1:
  • Collect the processed cell suspension incubate for a certain period of time, then centrifuge to discard the supernatant, resuspend the cells in the cell culture medium and continue culturing for 24 hours. After incubation, add Hoechst33342 solution, incubate for 15 minutes, discard the supernatant, wash twice with PBS, add 20 ⁇ L PBS, observe and take pictures with the oil lens (630 ⁇ ) of a confocal microscope. And collect the processed cell suspension, incubate for a certain period of time, centrifuge to discard the supernatant, resuspend the cells in PBS and wash twice, and analyze the delivery efficiency of the cells resuspended in PBS with a flow cytometer.
  • FIG. 6A and Figure 6B Flow cytometry analysis of the intracellular delivery efficiency of dextran in CT26 is shown in Figure 6A and Figure 6B, showing the intracellular delivery efficiency of 70kDa and 2MDa dextran, and the relationship between delivery efficiency and PET nuclear pore membrane pore diameter Under the condition of 8 micron pore diameter, both 70kDa and 2MDa glucan achieved the highest intracellular delivery efficiency.
  • Centrifuge the K562 single cell suspension add serum-free medium to resuspend the cells (cell concentration 1.2 ⁇ 10 6 cells/ml), and then add 70kDa or 2MDa dextran; nuclear pore membranes of different pore sizes are installed in the liposome for extrusion
  • the instrument LF1 transfer 1 ml of the K562 cell and dextran suspension into the device provided in Example 1 at room temperature (25 degrees Celsius), and then use the liposome extruder to push the cell suspension through the PET nuclear pore membrane.
  • the cell recovery rate is between 70-80% under the conditions of 7, 8 and 9 micron pore size; while under the condition of 10 micron pore size, the cell recovery rate reaches about 90%.
  • the cell recovery rate data shows that as the pore size of the nuclear pore membrane decreases, the cell recovery rate also decreases.
  • Comprehensive pore size, delivery efficiency and cell recovery rate it can be found that reducing the pore size can enhance the delivery efficiency, but will also lead to a decline in cell recovery rate. Therefore, the delivery test needs to maximize the delivery efficiency by optimizing the pore size while maintaining a certain cell recovery rate.
  • the pCMV-GFP plasmid was delivered to the nucleus of K562 cells and expressed the GFP protein.
  • the pCMV-GFP plasmid (Plasmid#11153, 4.4kbp) was combined with K562 cells using the device provided in Example 3.
  • the mixed suspension is passed through the microporous membrane 110, and then the green fluorescent protein GFP expression of K562 cells is detected by a confocal microscope, or the GFP expression level of K562 is analyzed by a flow cytometer.
  • the test materials are shown in Table 3:
  • Centrifuge the K562 single cell suspension resuspend the cells in serum-free medium (cell concentration 1.2 ⁇ 10 6 cells/ml), and then add pCMV-GFP plasmid; use the device provided in Example 3 with a PET nuclear pore membrane of 7 ⁇ m, At 30°C, transfer 2 mL of K562 cell and plasmid mixture into the device, use piston push rod 130 to push the cell suspension through the regular channels of PET nuclear membrane, collect the processed cell suspension, incubate for a certain time, and centrifuge Discard the supernatant, resuspend the cells in serum-containing medium and continue to culture for 2 hours, observe the expression of green fluorescent protein GFP with a confocal microscope; or continue to culture for 48 hours, analyze the expression of green fluorescent protein GFP with a flow cytometer.
  • CLSM observed the expression of pCMV-GFP plasmid in K562.
  • Figure 8 2 hours after the K562 and pCMV-GFP plasmid mixed suspension was extruded by the device provided in Example 3, GFP began to express, indicating that the pCMV-GFP plasmid was delivered into the K562 cell nucleus and transcribed into GFP-encoding mRNA, and finally the GFP protein is expressed in the nuclear ribosomes.
  • the expression of pCMV-GFP plasmid in K562 was analyzed by flow cytometry. As shown in Figure 9, 24 hours after the K562 and pCMV-GFP plasmid mixed suspension was extruded by the device provided in Example 3, the positive rate of GFP expression reached 49%, indicating that the delivery of pCMV-GFP plasmid into a larger proportion of K562 Cell nucleus, and express GFP protein.
  • the pCMV-GFP plasmid (Plasmid#11153, 4.4kbp) was delivered to the nucleus of CT26 cells and expressed the GFP protein.
  • 2 mL of the pCMV-GFP plasmid and CT26 single cell suspension were extruded using the device provided in Example 3.
  • the GFP expression level of CT26 at 48 hours was analyzed by flow cytometry.
  • the test materials are shown in Table 4:
  • 2MDa glucan is delivered into K562 cytoplasm and nucleus.
  • a suspension of 2MDa FITC-labeled dextran mixed with K562 cells was extruded using the device provided in Example 3.
  • the test materials are shown in Table 5:
  • Centrifuge the K562 single cell suspension add serum-free medium to resuspend the cells (cell concentration 1.2 ⁇ 10 6 cells/ml), then add 2MDa dextran; install the nuclear pore membrane in a device with temperature control accessories At 30°C, transfer 2 mL of K562 cell and dextran suspension into the device, and then use the plunger 130 to push the cell suspension through the regular channels of the PET nuclear membrane, collect the processed cell suspension, and add Hoechst 33342 Cell nuclear dye, incubate for a certain time, centrifuge to discard the supernatant, resuspend the cells in serum-free medium and wash twice, then resuspend in serum-free medium and add dropwise to a confocal dish, observe 2MDa dextran with a confocal microscope The distribution of sugar in the cytoplasm and nucleus.
  • the 2MDa dextran was delivered to CT26 (mouse colon cancer cell line) cells.
  • CT26 mae colon cancer cell line
  • This embodiment uses the device provided in Embodiment 3.
  • a cell suspension mixed with 2MDa dextran and CT26 was passed through a PET nuclear pore membrane with 9 micron pores at 4 degrees Celsius.
  • the test materials are shown in Table 6:
  • CT26 affects the cell recovery rate after extrusion.
  • CT26 cell suspensions with different cell densities were extruded using the device provided in Example 3. The cells were collected and the Invitrogen Countess II cell counter was used for cell counting and cell viability Detection.
  • Cell recovery rate (the number of living cells in the collected cell sample/the number of living cells in the cell suspension before treatment) ⁇ 100%
  • the cell recovery rate data is shown in Figure 13, showing that the higher the cell concentration, the lower the cell recovery rate.
  • the cell recovery rate under the conditions of 1 ⁇ 10 6 cells/ml and 2 ⁇ 10 6 cells/ml is greater than 80%.
  • a suitable cell concentration range needs to be selected to ensure a high cell recovery rate.
  • the molecular weight of foreign substances affects the efficiency of intracellular delivery. Delivery of 70kDa and 2MDa dextran to K562 cells. In order to evaluate the influence of the molecular weight of exogenous materials on the intracellular delivery efficiency, a suspension of 70kDa or 2MDa FITC-labeled dextran mixed with K562 cells was passed through the device provided in Example 1, and the intracellular delivery was analyzed by flow cytometry. effectiveness. The test materials are shown in Table 8:
  • Centrifuge the K562 single cell suspension add serum-free medium to resuspend the cells (cell concentration 1.2 ⁇ 10 6 cells/ml), and then add 70kDa or 2MDa dextran; nuclear pore membranes of different pore sizes are installed in the liposome for extrusion
  • the instrument LF1 transfer 1 ml of the K562 cell and dextran suspension into the device provided in Example 1 at room temperature (25 degrees Celsius), and then use the liposome extruder to push the cell suspension through the PET nuclear pore membrane.
  • Test results Flow cytometry analysis of the intracellular delivery efficiency of dextran in K562 is shown in Figure 14, showing the intracellular delivery efficiency of 70kDa and 2MDa dextran, as well as the relationship between dextran molecular weight and delivery efficiency.
  • the intracellular delivery efficiency of 2MDa glucan (FITC positive rate, MFI average fluorescence intensity) is less than 70kDa glucan, indicating exogenous The higher the molecular weight of the substance, the lower the efficiency of intracellular delivery.
  • 2MDa dextran was delivered to CT26 (mouse colon cancer cell line) cells.
  • CT26 mae colon cancer cell line
  • This embodiment uses the device provided in Embodiment 3.
  • 2MDa FITC-labeled dextran (FITC-dextran, hereinafter referred to as dextran) or pCMV-GFP plasmid DNA mixed with CT26 cell suspension was passed through Pass the PET nuclear pore membrane with 8 ⁇ m pores, use a cell counter to detect the cell recovery rate, and use a flow cytometer to analyze the intracellular delivery efficiency.
  • the dextran delivery test was performed under 5 temperature conditions (15°C, 20°C, 25°C, 30°C, 35°C), and the plasmid transfection test was performed under two temperature conditions (25°C, 30°C).
  • the test materials are shown in Table 9:
  • Collect the processed cell suspension incubate for a certain period of time, take samples for cell count detection, then centrifuge to discard the supernatant, resuspend the cells in PBS and wash twice, and analyze the delivery efficiency of the cells resuspended in PBS by flow cytometry.
  • For plasmid DNA transfection experiments collect the processed cell suspension, incubate for a certain period of time, centrifuge to discard the supernatant, resuspend in RPMI1640 medium containing FBS, culture for 48 hours, trypsinize the cells to prepare a single cell suspension, Flow cytometry was used to detect GFP expression.
  • the intracellular delivery efficiency and cell recovery rate of dextran in CT26 are shown in Figure 15, showing that temperature affects the intracellular delivery efficiency and cell recovery rate of 2MDa dextran. Under the condition of 8 micron pore size, as the temperature increases, The cell recovery rate increased, and 2MDa glucan achieved the highest intracellular delivery efficiency at 30°C, indicating that 30°C is the best delivery condition under the set 5 temperature conditions, which can obtain the highest cells.
  • the internal delivery efficiency can also obtain an optimized cell recovery rate.
  • CT26 has a higher GFP expression level (GFP positive rate and the average fluorescence intensity MFI of GFP expression) at 30°C, indicating the comparison It has better transfection effect at 25°C and 30°C.
  • the piston tube body in Example 2 is prepared from stainless steel by CNC machine tool processing; a PTFE rod is used to make a piston push rod that can be sealed with the tube body; the microporous membrane is detachably connected to the piston tube body Assembled into a piston unit in a way, the microporous membrane is located at the bottom of the piston tube.
  • the assembled piston unit and piston push rod are sterilized under high temperature, humidity and heat conditions (121.3°C, 20 minutes). After the sterilization is completed, they can be used for intracellular delivery test after drying and cooling.
  • the device provided by the present disclosure can deliver various foreign substances into eukaryotic cells.
  • the delivery process does not require the use of microfluidics and electric fields.
  • the present disclosure can deliver large foreign substances including plasmid DNA into the nucleus and express encoded proteins.
  • the present disclosure can realize high-throughput transfer of foreign substances to eukaryotic cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Sustainable Development (AREA)
  • Mechanical Engineering (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A device and a method for delivering exogenous substances into eukaryotic cells, and application thereof, relating to the field of biotechnology. The device for delivering exogenous substances into eukaryotic cells contains an extrusion module, wherein the extrusion module is provided with a microporous membrane having pores formed regularly, the diameter of each pore is smaller than that of an eukaryotic cell, and the extrusion module also comprises a pressure unit for driving eukaryotic cells and foreign substances to pass through the pores at the same time. Cells suspended in a solution can be compressed and deformed when passing through the pores, so that perforation of the cell membrane and nuclear membrane is caused so as to enable the exogenous substances dispersed or dissolved in the cell suspension to enter the cytoplasm and nucleus.

Description

外源物质递送至真核细胞内的装置和方法及其应用Device and method for delivering exogenous substances into eukaryotic cells and applications thereof
相关申请的交叉引用Cross references to related applications
本申请要求于2019年7月1日提交中国专利局的申请号为201910585544.1、名称为“外源物质递送至真核细胞内的装置和方法及其应用”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。This application claims the priority of the Chinese patent application filed with the Chinese Patent Office on July 1, 2019 with the application number 201910585544.1, entitled "Devices and methods for delivering foreign substances into eukaryotic cells and their applications", all of which The content is incorporated in this application by reference.
技术领域Technical field
本公开涉及生物技术领域,尤其是涉及一种外源物质递送至真核细胞内的装置和方法及其应用。The present disclosure relates to the field of biotechnology, in particular to a device and method for delivering exogenous substances into eukaryotic cells and their applications.
背景技术Background technique
细胞质和细胞核内递送是细胞工程、细胞疗法研发和许多生物学功能研究的关键步骤。现有的常规细胞内递送技术包括电穿孔、病毒载体或非病毒基因载体等。然而,这些方法有许多不足。比如电穿孔常导致较高的细胞死亡率;病毒载体具有免疫原性,构建递送特定序列核酸的病毒载体耗时长,效率低;非病毒基因载体在悬浮细胞和原代细胞的递送效率低,耗时较长,且不太适合递送除脱氧核糖核酸DNA和核糖核酸RNA外的其它生物大分子等(Stewart M P,Sharei A,Ding X,et al.In vitro and ex vivo strategies for intracellular delivery.Nature,2016,538(7624):183-192.)。此外,基于微流控的细胞内递送技术已出现,用于将各种外源性材料递送入各种细胞的细胞质(CN103987836B;Sharei,A.,et al.(2013).Cell Squeezing as a Robust,Microfluidic Intracellular Delivery Platform.Journal of Visualized Experiments:JoVE(81):50980.;CN201680051309.0A),但是其不能诱导核膜破裂并将水合半径大于细胞核膜核孔复合体(nuclear pore complex,NPC)扩散上限(Peters,R.(1984).Nucleo‐cytoplasmic flux and intracellular mobility in single hepatocytes measured by fluorescence microphotolysis.The EMBO Journal 3(8):1831-1836.)的超大分子量大分子如质粒DNA递送入细胞核(Ding,X.,et al.(2017).High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption.Nature Biomedical Engineering 1:0039.doi:10.1038/s41551-017-0039;Haiqing Bai et al.(2017).Cytoplasmic transport and nuclear import of plasmid DNABioscience Reports,37(6):1-17),且处理通量较低。Cytoplasmic and nuclear delivery are key steps in cell engineering, cell therapy research and development, and many biological functions. Existing conventional intracellular delivery technologies include electroporation, viral vectors, or non-viral gene vectors. However, these methods have many shortcomings. For example, electroporation often leads to higher cell mortality; viral vectors are immunogenic, and the construction of viral vectors that deliver specific sequence nucleic acids takes a long time and is low in efficiency; non-viral gene vectors have low delivery efficiency in suspension cells and primary cells. It takes a long time and is not suitable for delivering other biological macromolecules except deoxyribonucleic acid DNA and ribonucleic acid RNA (Stewart M P, Sharei A, Ding X, et al. In vitro and ex vivo strategies for intracellular delivery. Nature) ,2016,538(7624):183-192.). In addition, intracellular delivery technology based on microfluidics has emerged, which is used to deliver various exogenous materials into the cytoplasm of various cells (CN103987836B; Sharei, A., et al. (2013). Cell Squeezing as a Robust ,Microfluidic Intracellular Delivery Platform.Journal of Visualized Experiments:JoVE(81):50980.;CN201680051309.0A), but it cannot induce nuclear membrane rupture and the hydration radius is larger than the nuclear membrane nuclear pore complex (NPC) diffusion The upper limit (Peters, R. (1984). Nucleo-cytoplasmic flux and intracellular mobility in single hepatocytes measured by fluorescence microphotolysis. The EMBO Journal 3(8): 1831-1836.) The delivery of ultra-large molecular weight macromolecules such as plasmid DNA into the nucleus ( Ding,X.,et al.(2017).High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption. Nature Biomedical Engineering 1:0039.doi: 10.1038/s41551-017-0039; Haiqing Bai et al. (2017). Cytoplasmic transport and nuclear import of plasma DNA Bioscience Reports, 37(6): 1-17), and the processing throughput is low.
现有技术也有基于多孔膜的大分子递送系统可将微环DNA递送至人造血干细胞(WO2018064387A1,CN201780060638.6)细胞核并表达GFP基因。然而,该递送系统具有如下缺陷,单通道装置的细胞悬液处理体积小(仅50μL)、悬液中细胞密度过高(高达~10 7个细胞/毫升)及其导致的细胞回收率较低(12%到57%)、以及微环DNA(碱基对数量约0.7kbp)转染效率极低(1%到8.4%)。 The prior art also has a porous membrane-based macromolecule delivery system that can deliver microcircle DNA to the nucleus of artificial hematopoietic stem cells (WO2018064387A1, CN201780060638.6) and express the GFP gene. However, this delivery system has the following drawbacks: the single-channel device has a small processing volume of cell suspension (only 50 μL), high cell density in the suspension (up to -10 7 cells/ml) and the resulting low cell recovery rate (12% to 57%), and minicircle DNA (the number of base pairs is about 0.7kbp) transfection efficiency is extremely low (1% to 8.4%).
此外,现有技术中关于递送温度与细胞内大分子递送效率关系的研究显示,温度对递送效率的影响较小(Sharei,A.,et al.(2013)."A vector-free microfluidic platform for intracellular delivery."Proceedings of the National Academy of Sciences 110(6):2082-2087.),但是该研究所采用的温度控制措施是将装置置于冰浴或置于室温,从而只能得到有限的温度控制效果。In addition, studies on the relationship between the delivery temperature and the delivery efficiency of intracellular macromolecules in the prior art show that temperature has a small effect on delivery efficiency (Sharei, A., et al. (2013). "A vector-free microfluidic platform for intracellular delivery."Proceedings of the National Academy of Sciences 110(6):2082-2087.), but the temperature control measures adopted by the institute are to place the device in an ice bath or at room temperature, so that only a limited temperature can be obtained Control effect.
本公开基于对前述技术缺陷及对考察温度与细胞内大分子递送效率关系的关注,设计了带温控模块的装置,并进行了各种大分子递送和质粒DNA转染试验。Based on the aforementioned technical deficiencies and concerns about the relationship between temperature and the delivery efficiency of intracellular macromolecules, this disclosure has designed a device with a temperature control module, and conducted various macromolecule delivery and plasmid DNA transfection experiments.
发明内容Summary of the invention
本公开提供一种将外源物质递送至真核细胞内的装置,该装置缓解了现有真核细胞内递送技术的不足,比如无法使细胞核膜破裂穿孔,为了递送质粒DNA进入细胞核需要联用微流控和电场,以及基于载体的细胞内递送方法仅适合递送特定分子诸如核酸等技术问题。The present disclosure provides a device for delivering exogenous substances into eukaryotic cells. The device alleviates the deficiencies of the existing eukaryotic intracellular delivery technology, such as the inability to rupture and perforate the nuclear membrane of the cell. In order to deliver plasmid DNA into the nucleus, a combination is required Microfluidics and electric fields, as well as carrier-based intracellular delivery methods are only suitable for technical problems such as the delivery of specific molecules such as nucleic acids.
本公开提供一种外源物质递送至真核细胞内的装置,这种装置在单次递送试验可以处理较高的细胞悬液体积,降低细胞密度,从而获得更好的细胞回收率和存活率。The present disclosure provides a device for delivering exogenous substances into eukaryotic cells. This device can process a higher cell suspension volume and reduce cell density in a single delivery test, thereby obtaining better cell recovery and survival rates .
本公开提供一种带温控模块的装置,通过改变递送温度,以实现更高的递送效率和更高的细胞回收率。The present disclosure provides a device with a temperature control module, which can achieve higher delivery efficiency and higher cell recovery rate by changing the delivery temperature.
本公开还提供一种外源物质递送至真核细胞内的方法,该方法包括将真核细胞和外源物质的混合物经本公开所述装置挤出。The present disclosure also provides a method for delivering exogenous substances into eukaryotic cells, the method comprising extruding a mixture of eukaryotic cells and exogenous substances through the device of the present disclosure.
本公开提供一种高通量真核细胞内递送装置,或将外源物质递送至真核细胞内的方法在调控细胞功能功能中的应用。The present disclosure provides an application of a high-throughput eukaryotic intracellular delivery device or a method for delivering exogenous substances into eukaryotic cells in regulating cell functions.
本公开提供了一种外源物质递送至真核细胞内的装置,该装置包含挤出模块,所述挤出模块中设置分布有规则孔道的微孔膜,所述孔道的孔径小于所述真核细胞的直径;所述挤出模块还包括用于驱动真核细胞和外源物质同时通过孔道的压力单元;在一种或多种实施方式中,所述压力单元包括活塞单元或压缩气体驱动单元。在一种或多种实施方式中,所述装置还包括温控模块,用于控制挤出模块和细胞悬液体系的环境温度。The present disclosure provides a device for delivering exogenous substances into eukaryotic cells. The device includes an extrusion module in which a microporous membrane with regular pores is arranged, and the pore diameter of the pores is smaller than that of the true cell. The diameter of the nuclear cell; the extrusion module also includes a pressure unit for driving eukaryotic cells and exogenous substances through the pores at the same time; in one or more embodiments, the pressure unit includes a piston unit or a compressed gas drive unit. In one or more embodiments, the device further includes a temperature control module for controlling the environmental temperature of the extrusion module and the cell suspension system.
本公开还提供了一种外源物质递送至真核细胞内的方法,该方法包括:将包含真核细胞和外源物质的混悬体系经上述装置挤出,以使外源物质递送至真核细胞内。The present disclosure also provides a method for delivering exogenous substances into eukaryotic cells, the method comprising: extruding a suspension system containing eukaryotic cells and exogenous substances through the above-mentioned device, so that the exogenous substances are delivered to the eukaryotic cells. Nuclear cell.
本公开还提供了上述高通量真核细胞内递送装置,或上述外源物质递送至真核细胞内的方法在调控细胞功能中的应用。The present disclosure also provides the application of the above-mentioned high-throughput eukaryotic intracellular delivery device, or the above-mentioned method of delivering exogenous substances into eukaryotic cells, in regulating cell functions.
与现有技术相比,本公开的有益效果至少包括:Compared with the prior art, the beneficial effects of the present disclosure include at least:
本公开提供的外源物质递送至真核细胞内的装置设置有挤出模块,该挤出模块中设置分布有规则孔道的微孔膜,且孔道的孔径小于所述真核细胞直径;该挤出模块还包括用于驱动真核细胞和外源物质同时通过孔道的活塞单元;所述装置还包括温控模块,用于控制挤出模块和细胞悬液体系的环境温度。The device for delivering exogenous substances into eukaryotic cells provided by the present disclosure is provided with an extrusion module in which a microporous membrane with regular pores is arranged, and the pore diameter of the pores is smaller than the diameter of the eukaryotic cell; The output module also includes a piston unit for driving eukaryotic cells and exogenous substances through the pores at the same time; the device also includes a temperature control module for controlling the environmental temperature of the extrusion module and the cell suspension system.
悬浮在溶液中的细胞可以在穿过孔道的过程中压缩变形,从而引起细胞膜和核膜穿孔,使得分散或溶解在细胞悬液中的外源性材料进入细胞质和细胞核。本公开提供的真核细胞内递送方法克服了现有细胞内递送技术的不足,例如基于核孔膜的细胞内递送技术细胞处理体积过小(50μL)、细胞密度过高(高达~10 7个细胞/毫升)、微环DNA转染效率极低(1%到8.4%)、以及微环DNA递送时细胞回收率(12%到57%)较低等,例如基于微流控的细胞内递送技术无法使细胞核膜破裂穿孔;或为了递送质粒DNA进入细胞核需要联用微流控和电场,以及基于非病毒基因载体的细胞内递送方法仅适合递送特定分子如核酸等技术问题。 The cells suspended in the solution can be compressed and deformed in the process of passing through the pores, thereby causing the cell membrane and nuclear membrane to perforate, so that the exogenous materials dispersed or dissolved in the cell suspension enter the cytoplasm and nucleus. The eukaryotic intracellular delivery method provided by the present disclosure overcomes the shortcomings of the existing intracellular delivery technology, such as the intracellular delivery technology based on nuclear pore membrane. The cell processing volume is too small (50 μL) and the cell density is too high (up to -10 7 cells). Cells/ml), minicircle DNA transfection efficiency is extremely low (1% to 8.4%), and the cell recovery rate (12% to 57%) of minicircle DNA delivery is low, such as intracellular delivery based on microfluidics Technology cannot rupture and perforate the nuclear membrane of the cell; or in order to deliver plasmid DNA into the nucleus, a combination of microfluidics and electric fields are required, and intracellular delivery methods based on non-viral gene vectors are only suitable for the delivery of specific molecules such as nucleic acids.
本公开提供的外源物质递送至真核细胞内的装置不仅能将各种分子量的外源物质递送入细胞质,还能将水合半径大于细胞核膜孔复合体(nuclear pore complex,NPC)扩散上限的外源物质,诸如2MDa FITC-dextran,高效率递送入细胞核。因此说明本公开通过同时诱导细胞膜和核膜破裂、穿孔,实现了细胞质和细胞核内递送。其次,本公开提供的装置能将水合半径更大的质粒DNA高效递送入细胞核,并表达其编码的蛋白质。第三,本公开能将各种类型的外源性材料递送入细胞质及细胞核,不受材料自身理化特性的限制,例如葡聚糖和质粒DNA。第四,本公开在递送质粒DNA进入细胞核并表达相应蛋白质时无需电场辅助。第五,本公开提供的装置适合较高通量地使含有细胞的体系穿过微孔膜,单次处理含有细胞的悬液至少可达0.5mL,一次挤出的细胞总数量至少可达0.6×10 6个。 The device for delivering exogenous substances into eukaryotic cells provided in the present disclosure can not only deliver exogenous substances of various molecular weights into the cytoplasm, but also deliver a hydration radius larger than the upper limit of the diffusion of the nuclear pore complex (NPC) Exogenous substances, such as 2MDa FITC-dextran, are delivered into the nucleus with high efficiency. Therefore, it is shown that the present disclosure achieves cytoplasmic and nuclear delivery by simultaneously inducing rupture and perforation of cell membrane and nuclear membrane. Secondly, the device provided by the present disclosure can efficiently deliver plasmid DNA with a larger hydration radius into the cell nucleus and express the encoded protein. Third, the present disclosure can deliver various types of exogenous materials into the cytoplasm and nucleus without being restricted by the physical and chemical properties of the materials themselves, such as dextran and plasmid DNA. Fourth, the present disclosure does not require electric field assistance when delivering plasmid DNA into the nucleus and expressing the corresponding protein. Fifth, the device provided by the present disclosure is suitable for high-throughput cell-containing system through the microporous membrane, a single treatment of cell-containing suspension can reach at least 0.5 mL, and the total number of cells extruded at one time can reach at least 0.6 ×10 6 pcs.
基于该装置,本公开还提供了外源物质递送至真核细胞内的方法,该方法包括将真核细胞和外源物质的混合物经上述装置挤出。因此具有上述装置的所有有益效果,在此不再赘述。Based on this device, the present disclosure also provides a method for delivering exogenous substances into eukaryotic cells, the method comprising extruding a mixture of eukaryotic cells and exogenous substances through the aforementioned device. Therefore, it has all the beneficial effects of the above device, which will not be repeated here.
附图说明Description of the drawings
为了更清楚地说明本公开具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本公开的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to more clearly describe the specific embodiments of the present disclosure or the technical solutions in the prior art, the following will briefly introduce the drawings that need to be used in the specific embodiments or the description of the prior art. Obviously, the appendix in the following description The drawings are some embodiments of the present disclosure. For those of ordinary skill in the art, other drawings may be obtained based on these drawings without creative work.
图1为本公开提供的外源物质递送至真核细胞内的装置的原理示意图;Figure 1 is a schematic diagram of the principle of a device for delivering foreign substances into eukaryotic cells provided by the present disclosure;
图2A为本公开实施例1-3使用的聚对苯二甲酸乙二醇酯(PET)核孔膜;Figure 2A is a polyethylene terephthalate (PET) nuclear porous membrane used in Examples 1-3 of the present disclosure;
图2B为本公开实施例1-3使用的PET核孔膜上的孔道;Figure 2B shows the pores on the PET nuclear porous membrane used in Examples 1-3 of the present disclosure;
图2C为本公开实施例1提供的外源物质递送至真核细胞内的装置;2C is a device for delivering exogenous substances into eukaryotic cells provided in Example 1 of the present disclosure;
图3为本公开实施例2提供的外源物质递送至真核细胞内的装置;Fig. 3 is a device for delivering exogenous substances into eukaryotic cells provided in Example 2 of the disclosure;
图4为本公开实施例3提供的外源物质递送至真核细胞内的装置;4 is a device for delivering exogenous substances into eukaryotic cells provided in Example 3 of the disclosure;
图5A为本公开实施例4中70kDa葡聚糖递送至CT26细胞质和细胞核的共聚焦图片;5A is a confocal picture of 70kDa glucan delivered to CT26 cytoplasm and nucleus in Example 4 of the disclosure;
图5B为本公开实施例4中2MDa葡聚糖递送至CT26细胞质和细胞核的共聚焦图片;Figure 5B is a confocal picture of 2MDa glucan delivered to CT26 cytoplasm and nucleus in Example 4 of the disclosure;
图6A为本公开实施例4中70kDa葡聚糖递送至CT26细胞递送效率的流式检测数据;6A is the flow cytometry data of the delivery efficiency of 70kDa glucan to CT26 cells in Example 4 of the disclosure;
图6B为本公开实施例4中2MDa葡聚糖递送至CT26细胞递送效率的流式检测数据;6B is the flow cytometry data of the delivery efficiency of 2MDa glucan to CT26 cells in Example 4 of the disclosure;
图7A为本公开实施例5中70kDa葡聚糖递送至K562细胞递送效率的流式检测数据;Figure 7A is the flow cytometric data of the delivery efficiency of 70kDa glucan to K562 cells in Example 5 of the disclosure;
图7B为本公开实施例5中2MDa葡聚糖递送至K562细胞递送效率的流式检测数据;7B is the flow cytometry data of the delivery efficiency of 2MDa glucan to K562 cells in Example 5 of the disclosure;
图7C为本公开实施例5中不同孔径核孔膜条件下K562细胞回收率;7C shows the recovery rate of K562 cells under different pore size nuclear pore membrane conditions in Example 5 of the disclosure;
图8为本公开实施例6中pCMV-GFP质粒递送到K562细胞核并表达GFP蛋白的共聚焦图片;Figure 8 is a confocal picture of pCMV-GFP plasmid delivered to K562 cell nucleus and expressing GFP protein in Example 6 of the disclosure;
图9为本公开实施例6中pCMV-GFP质粒递送到K562细胞核并表达GFP蛋白的流式检测数据;Figure 9 is the flow cytometry data of pCMV-GFP plasmid delivered to K562 cell nucleus and expressing GFP protein in Example 6 of the disclosure;
图10为本公开实施例7中pCMV-GFP质粒递送到CT26细胞核并表达GFP蛋白的流式检测数据;Figure 10 is the flow cytometry data of pCMV-GFP plasmid delivered to CT26 cell nucleus and expressing GFP protein in Example 7 of the disclosure;
图11为本公开实施例8提供的2MDa葡聚糖递送到K562细胞质和细胞核的共聚焦图片;Figure 11 is a confocal picture of the delivery of 2MDa glucan to K562 cytoplasm and nucleus provided in Example 8 of the disclosure;
图12为本公开实施例9提供的2MDa葡聚糖递送到CT26细胞的流式检测数据;Figure 12 is the flow cytometric data of 2MDa glucan delivered to CT26 cells provided in Example 9 of the disclosure;
图13为本公开实施例10提供的不同密度CT26悬液挤出处理后的细胞回收率;FIG. 13 is the cell recovery rate after extrusion treatment of the CT26 suspension with different density provided in Example 10 of the disclosure;
图14为本公开实施例11提供的不同分子量外源物质在相同孔径核孔膜条件下的K562细胞内递送效率;Figure 14 shows the intracellular delivery efficiency of K562 cells with different molecular weight exogenous substances provided in Example 11 of the disclosure under the same pore size nuclear pore membrane condition;
图15A为本公开实施例12提供的不同温度下2MDa FITC-dextram在CT26细胞内递送效率和细胞回收率;15A shows the delivery efficiency and cell recovery rate of 2MDa FITC-dextram in CT26 cells at different temperatures provided in Example 12 of the disclosure;
图15B为本公开实施例12提供的不同温度下pDNA在CT26细胞的转染效率;15B shows the transfection efficiency of pDNA in CT26 cells at different temperatures provided in Example 12 of the disclosure;
具体实施方式Detailed ways
下面将结合实施例对本公开的技术方案进行清楚、完整地描述,显然,所描述的实施例是本公开一部分实施例,而不是全部的实施例。基于本公开中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本公开保护的范围。The technical solutions of the present disclosure will be clearly and completely described below in conjunction with embodiments. Obviously, the described embodiments are part of the embodiments of the present disclosure, but not all of the embodiments. Based on the embodiments in the present disclosure, all other embodiments obtained by those of ordinary skill in the art without creative work shall fall within the protection scope of the present disclosure.
本公开提供了一种外源物质递送至真核细胞内的装置,该装置包含挤出模块,所述挤出模块中设置分布有规则孔道的微孔膜,所述孔道的孔径小于所述真核细胞直径;所述挤出模块还包括用于驱动真核细胞和外源物质同时通过孔道的活塞单元。The present disclosure provides a device for delivering exogenous substances into eukaryotic cells. The device includes an extrusion module in which a microporous membrane with regular pores is arranged, and the pore diameter of the pores is smaller than that of the true cell. Nuclear cell diameter; the extrusion module also includes a piston unit for driving eukaryotic cells and foreign substances through the pores at the same time.
挤出模块在活塞单元的驱动下使细胞在穿过孔道的过程中变形,从而引起细胞膜和细胞核膜穿孔及通透性增加,使得分散在细胞周围的外源物质进入细胞,以及细胞核中,原 理如图1所示。规则孔道指的是微孔膜上的孔道的形状均一,为圆形或近圆形。由于本公开提供的外源物质递送至细胞内的装置适合较高通量的细胞穿过,因此由于每次穿过挤出膜的细胞数量大,如果微孔膜上的孔道不规则,其截面形状存在较大的差异,则细胞死亡率会较高。本公开中所述的“细胞”也指代“真核细胞”。可以理解的是,所述装置还包括在细胞和外源物质通过微孔膜前的贮存空间,和挤出后用于接收挤出物的接收空间。本公开对贮存空间和接收空间的形状、体积和材质,以及贮存空间、微孔膜和接收空间的连接方式均不作限制,只要能使细胞和外源物质从贮存空间通过微孔膜,以及从微孔膜至接受空间之间的流通即可。可以理解的是,该装置可以独立使用,也可以和其他装置配合使用以组成一个系统。The extrusion module is driven by the piston unit to deform the cells during the process of passing through the pores, thereby causing the cell membrane and the nuclear membrane to perforate and increase the permeability, so that the foreign substances scattered around the cell enter the cell and the nucleus. Principle As shown in Figure 1. Regular pores refer to the uniform shape of the pores on the microporous membrane, which are round or nearly round. Since the device for delivering exogenous substances into cells provided in the present disclosure is suitable for the passage of higher flux cells, since the number of cells passing through the extruded membrane each time is large, if the pores on the microporous membrane are irregular, the cross-section There is a greater difference in shape, the cell death rate will be higher. The "cell" described in the present disclosure also refers to "eukaryotic cells". It can be understood that the device also includes a storage space before the cells and foreign substances pass through the microporous membrane, and a receiving space for receiving the extrudate after extrusion. The present disclosure does not limit the shape, volume and material of the storage space and the receiving space, as well as the connection mode of the storage space, the microporous membrane and the receiving space, as long as the cells and foreign substances can pass from the storage space through the microporous membrane, and from The flow between the microporous membrane and the receiving space is sufficient. It is understandable that the device can be used independently or in conjunction with other devices to form a system.
在一种或多种实施方式中,挤出模块的温度为28-31℃,例如28-30℃,例如30℃。在一种或多种实施方式中,挤出模块的温度为例如28.2℃、28.4℃、28.6℃、28.8℃、29℃、29.2℃、29.4℃、29.6℃、29.8℃或30℃。In one or more embodiments, the temperature of the extrusion module is 28-31°C, such as 28-30°C, such as 30°C. In one or more embodiments, the temperature of the extrusion module is, for example, 28.2°C, 28.4°C, 28.6°C, 28.8°C, 29°C, 29.2°C, 29.4°C, 29.6°C, 29.8°C, or 30°C.
在一种或多种实施方式中,包含真核细胞和外源物质的混悬体系中的真核细胞浓度为1×10 6个细胞/毫升至4×10 6个细胞/毫升,例如1×10 6个细胞/毫升至2×10 6个细胞/毫升。在一种或多种实施方式中,包含真核细胞和外源物质的混悬体系中的真核细胞浓度为1.2×10 6个细胞/毫升、1.4×10 6个细胞/毫升、1.6×10 6个细胞/毫升、1.8×10 6个细胞/毫升、2.0×10 6个细胞/毫升、2.2×10 6个细胞/毫升、2.4×10 6个细胞/毫升、2.6×10 6个细胞/毫升、2.8×10 6个细胞/毫升、3.0×10 6个细胞/毫升、3.2×10 6个细胞/毫升、3.4×10 6个细胞/毫升、3.6×10 6个细胞/毫升、3.8×10 6个细胞/毫升或4.0×10 6个细胞/毫升。 In one or more embodiments, the eukaryotic cell concentration in the suspension system containing eukaryotic cells and exogenous substances is 1×10 6 cells/ml to 4×10 6 cells/ml, for example, 1×10 6 cells/ml. 10 6 cells/ml to 2×10 6 cells/ml. In one or more embodiments, the eukaryotic cell concentration in the suspension system containing eukaryotic cells and exogenous substances is 1.2×10 6 cells/ml, 1.4×10 6 cells/ml, 1.6×10 6 cells/ml, 1.8×10 6 cells/ml, 2.0×10 6 cells/ml, 2.2×10 6 cells/ml, 2.4×10 6 cells/ml, 2.6×10 6 cells/ml , 2.8×10 6 cells/ml, 3.0×10 6 cells/ml, 3.2×10 6 cells/ml, 3.4×10 6 cells/ml, 3.6×10 6 cells/ml, 3.8×10 6 Cells/ml or 4.0×10 6 cells/ml.
在一种或多种实施方式中,所述微孔膜的材质包括金属或非金属。在一种或多种实施方式中,所述微孔膜的材质包括非金属,所述非金属包括但不限于聚合物、陶瓷或硅。例如微孔膜的材质是聚合物。以聚合物为基材制备得到的微孔膜,孔道分布均匀,微孔膜更轻薄。所述聚合物包括但不限于聚对苯二甲酸乙二醇酯、聚四氟乙烯、聚碳酸酯、聚酰亚胺、聚酰胺、醋酸纤维素、硝酸纤维素、聚乙烯、聚醚砜或聚四氟乙烯;例如聚对苯二甲酸乙二醇酯或聚酰亚胺或聚碳酸酯。所述聚合物为选自由聚对苯二甲酸乙二醇酯、聚四氟乙烯、聚碳酸酯、聚酰亚胺、聚酰胺、醋酸纤维素、硝酸纤维素、聚乙烯、聚醚砜和聚四氟乙烯组成的组中的至少一种。In one or more embodiments, the material of the microporous membrane includes metal or non-metal. In one or more embodiments, the material of the microporous membrane includes non-metal, and the non-metal includes, but is not limited to, polymer, ceramic, or silicon. For example, the material of the microporous membrane is polymer. The microporous membrane prepared by using the polymer as the substrate has uniform pore distribution, and the microporous membrane is lighter and thinner. The polymer includes but is not limited to polyethylene terephthalate, polytetrafluoroethylene, polycarbonate, polyimide, polyamide, cellulose acetate, nitrocellulose, polyethylene, polyethersulfone or Polytetrafluoroethylene; for example, polyethylene terephthalate or polyimide or polycarbonate. The polymer is selected from polyethylene terephthalate, polytetrafluoroethylene, polycarbonate, polyimide, polyamide, cellulose acetate, nitrocellulose, polyethylene, polyethersulfone, and polyethersulfone. At least one of the group consisting of tetrafluoroethylene.
在一种或多种实施方式中,制备微孔膜上的孔道的方法包括蚀刻或打孔,蚀刻优选径迹蚀刻或光蚀刻,光蚀刻优选激光蚀刻;打孔优选使用冲压打孔。在一种或多种实施方式中,采用径迹蚀刻制备得到微孔膜,效果更佳。In one or more embodiments, the method for preparing the pores on the microporous film includes etching or perforating. The etching is preferably track etching or photoetching, and the photoetching is preferably laser etching; and punching is preferably used for perforating. In one or more embodiments, the microporous film is prepared by track etching, which has better effect.
如本文所用,术语“核孔膜”也称“核径迹膜(nuclear track membrane)”或“核径迹蚀刻膜(nuclear track-etch membrane)”,一般是指通过辐照径迹-化学刻蚀技术获得的非金属膜。核孔膜具有独特的微孔特性、孔径均一,被广泛地用于膜分离领域。As used herein, the term "nuclear pore membrane" is also called "nuclear track membrane" or "nuclear track-etch membrane", which generally refers to radiation track-chemical engraving Non-metallic film obtained by etching technology. Nuclear porous membranes have unique microporous characteristics and uniform pore size, and are widely used in the field of membrane separation.
在一种或多种实施方式中,所述微孔膜为核孔膜。In one or more embodiments, the microporous membrane is a nuclear porous membrane.
在一种或多种实施方式中,所述活塞单元向细胞和外源物质施加正压力,活塞单元可以由人工手动驱动,也可以由驱动单元驱动。在一种或多种实施方式中,也可用压缩气体驱动。In one or more embodiments, the piston unit applies positive pressure to the cells and exogenous substances, and the piston unit may be manually driven by hand or driven by a driving unit. In one or more embodiments, it can also be driven by compressed gas.
在一种或多种实施方式中,所述活塞单元包括活塞管体和活塞推杆。在一种或多种实施方式中,活塞单元包括用于驱动活塞推杆的驱动单元,驱动单元可选择常规的能够提供动力的单元,例如使用电机驱动活塞运动,以向细胞和外源物质施加朝向微孔膜方向的正压力。In one or more embodiments, the piston unit includes a piston tube and a piston push rod. In one or more embodiments, the piston unit includes a driving unit for driving the piston push rod, and the driving unit can select a conventional unit capable of providing power, for example, using a motor to drive the piston to move, so as to apply cells and foreign substances. Positive pressure towards the microporous membrane.
在一种或多种实施方式中,活塞管体的材质包括金属材料、合金材料或玻璃除外的非金属材料;在一种或多种实施方式中,金属材料包括铝或铜;在一种或多种实施方式中,合金材料包括不锈钢或钛镁合金。In one or more embodiments, the material of the piston tube body includes metal materials, alloy materials, or non-metallic materials other than glass; in one or more embodiments, the metal material includes aluminum or copper; In various embodiments, the alloy material includes stainless steel or titanium-magnesium alloy.
在一种或多种实施方式中,活塞推杆主要由天然高分子材料或合成高分子材料制备得到。在一种或多种实施方式中,天然高分子材料为橡胶。在一种或多种实施方式中,合成 高分子材料为聚酯类。在一种或多种实施方式中,合成高分子材料为聚四氟乙烯和/或聚乙烯。在一种或多种实施方式中,使用聚对苯二甲酸乙二醇酯材料制备活塞推杆。在一种或多种实施方式中,使用聚乙烯或聚四氟乙烯共同构成的活塞单元;在一种或多种实施方式中,选取聚乙烯材料的活塞单元。合成高分子材料机械强度好,耐腐蚀且表面光滑,尤其是以聚酯、聚乙烯和聚四氟乙烯性能较佳。In one or more embodiments, the piston push rod is mainly made of natural polymer materials or synthetic polymer materials. In one or more embodiments, the natural polymer material is rubber. In one or more embodiments, the synthetic polymer material is polyester. In one or more embodiments, the synthetic polymer material is polytetrafluoroethylene and/or polyethylene. In one or more embodiments, a polyethylene terephthalate material is used to prepare the piston push rod. In one or more embodiments, a piston unit composed of polyethylene or polytetrafluoroethylene is used; in one or more embodiments, a piston unit made of polyethylene is selected. Synthetic polymer materials have good mechanical strength, corrosion resistance and smooth surface, especially polyester, polyethylene and polytetrafluoroethylene.
在一种或多种实施方式中,所述装置还包括温控模块,温控模块用于给挤出模块提供恒定的温度,使细胞和外源物质能够在指定的温度条件下挤出。所述温控模块与挤出模块接触,使温度更直接的传递至挤出模块中以控制挤出模块的温度。例如在挤出模块中用于贮存细胞和外源物质的空间的外壁设置发热金属丝、陶瓷加热器、半导体制冷片或流体循环控温单元等。在一种或多种实施方式中,所述流体循环控温单元设置有和挤出模块接触的腔体,所述腔体用于流体循环控温单元中的流体流通。In one or more embodiments, the device further includes a temperature control module, which is used to provide a constant temperature to the extrusion module, so that cells and foreign substances can be extruded under a specified temperature condition. The temperature control module is in contact with the extrusion module, so that the temperature is more directly transferred to the extrusion module to control the temperature of the extrusion module. For example, heating metal wires, ceramic heaters, semiconductor refrigeration fins or fluid circulation temperature control units are arranged on the outer wall of the space for storing cells and exogenous substances in the extrusion module. In one or more embodiments, the fluid circulation temperature control unit is provided with a cavity in contact with the extrusion module, and the cavity is used for fluid circulation in the fluid circulation temperature control unit.
在一种或多种实施方式中,所述装置还包括温控模块,所述温控模块配置成通过与挤出模块接触以控制挤出模块和混悬液形式的真核细胞及外源物质的温度。In one or more embodiments, the device further includes a temperature control module configured to control the eukaryotic cells and exogenous substances in the form of the extrusion module and the suspension by contacting the extrusion module temperature.
在一种或多种实施方式中,所述温控模块包括流体循环控温单元或半导体制冷单元。In one or more embodiments, the temperature control module includes a fluid circulation temperature control unit or a semiconductor refrigeration unit.
在一种或多种实施方式中,所述流体循环控温单元设置有和挤出模块接触的腔体,所述腔体配置成用于流体循环控温单元中的流体流通。In one or more embodiments, the fluid circulation temperature control unit is provided with a cavity in contact with the extrusion module, and the cavity is configured for fluid circulation in the fluid circulation temperature control unit.
在一种或多种实施方式中,所述压力单元是活塞单元,所述活塞单元配置成驱动混悬液形式的真核细胞及外源物质同时通过孔道。In one or more embodiments, the pressure unit is a piston unit, and the piston unit is configured to drive eukaryotic cells and foreign substances in a suspension form through the pores at the same time.
在一种或多种实施方式中,所述活塞单元配置成向细胞和外源物质施与正压力,以使细胞和外源物质通过所述孔道。In one or more embodiments, the piston unit is configured to apply a positive pressure to the cells and the foreign substance, so that the cells and the foreign substance pass through the pores.
在一种或多种实施方式中,所述活塞单元包括活塞管体和活塞推杆。In one or more embodiments, the piston unit includes a piston tube and a piston push rod.
在一种或多种实施方式中,所述活塞单元包括用于驱动活塞推杆的驱动单元。In one or more embodiments, the piston unit includes a driving unit for driving the piston push rod.
在一种或多种实施方式中,所述微孔膜与所述活塞管体可拆卸连接。In one or more embodiments, the microporous membrane is detachably connected to the piston tube body.
在一种或多种实施方式中,所述活塞管体的材质包括金属材料、合金材料或除玻璃外的非金属材料。In one or more embodiments, the material of the piston tube body includes metal materials, alloy materials or non-metal materials other than glass.
在一种或多种实施方式中,所述除玻璃外的非金属材料包括塑料。In one or more embodiments, the non-metallic material other than glass includes plastic.
在一种或多种实施方式中,所述除玻璃外的非金属材料包括高分子材料。In one or more embodiments, the non-metallic materials other than glass include polymer materials.
在一种或多种实施方式中,所述活塞推杆的材质包括天然高分子材料或合成高分子材料。In one or more embodiments, the material of the piston push rod includes natural polymer materials or synthetic polymer materials.
本公开还提供了一种外源物质递送至真核细胞内的方法,该方法包括将真核细胞和外源物质的混悬体系经上述装置挤出。本公开所述的混悬体系,指的是分散有真核细胞和外源物质的体系,该体系的分散介质可以为常规的可维持真核细胞活性的介质,包括但不限于培养基、生理盐水以及PBS缓冲液等。本公开所述的递送,指的是使外源物质进入细胞中,即外源物质进入细胞质,或外源物质进入细胞质和细胞核中。The present disclosure also provides a method for delivering exogenous substances into eukaryotic cells, the method comprising extruding a suspension system of eukaryotic cells and exogenous substances through the above-mentioned device. The suspension system described in the present disclosure refers to a system in which eukaryotic cells and exogenous substances are dispersed. The dispersion medium of the system can be a conventional medium that can maintain the activity of eukaryotic cells, including but not limited to medium, physiological Saline and PBS buffer, etc. The delivery described in the present disclosure refers to the introduction of foreign substances into cells, that is, foreign substances into the cytoplasm, or foreign substances into the cytoplasm and nucleus.
本公开提供的外源物质递送至真核细胞内的方法可以在室温下进行,本公开所述的室温指的是未经人为干预的环境温度。在一种或多种实施方式中,细胞和外源物质在挤出时,挤出模块的温度和环境温度相近。The method for delivering exogenous substances into eukaryotic cells provided in the present disclosure can be performed at room temperature, and the room temperature described in the present disclosure refers to an ambient temperature without human intervention. In one or more embodiments, when the cells and foreign substances are extruded, the temperature of the extrusion module is similar to the ambient temperature.
在一种或多种实施方式中,在预设温度下将外源物质递送至真核细胞内。在预设温度下将外源物质递送至真核细胞内具有更高的递送效率、细胞回收率和存活率。因此所述外源物质递送至真核细胞内的方法在预设的温度下进行。所述预设的温度由所述外源物质递送至真核细胞内的装置的温控模块进行调控。In one or more embodiments, the exogenous substance is delivered into eukaryotic cells at a preset temperature. Delivering exogenous substances into eukaryotic cells at a preset temperature has higher delivery efficiency, cell recovery rate and survival rate. Therefore, the method of delivering the exogenous substance into eukaryotic cells is performed at a preset temperature. The preset temperature is regulated by the temperature control module of the device for delivering the exogenous substance into the eukaryotic cells.
在一种或多种实施方式中,包含细胞和外源物质的混悬体系一次性经所述装置挤出;其中一次性经所述装置挤出指的是施与混合物持续的压力,使混合物不间断的穿过微孔膜。In one or more embodiments, the suspension system containing cells and exogenous substances is extruded through the device at one time; wherein extruding through the device at one time refers to applying continuous pressure to the mixture to make the mixture Uninterrupted through the microporous membrane.
在一种或多种实施方式中,一次性经所述装置挤出的混悬体系的体积至少为0.5mL。例如,单次穿过微孔膜的混合物中的细胞数量至少为0.6×10 6个。该方法能够处理较大通量 的细胞,具有单次细胞悬液处理体积较高(>0.5毫升)、单次处理细胞通量较高(>0.6×10 6个细胞)的优点。 In one or more embodiments, the volume of the suspension system extruded through the device at one time is at least 0.5 mL. For example, the number of cells in the mixture passing through the microporous membrane in a single pass is at least 0.6×10 6 cells. The method can process cells with a larger flux, and has the advantages of a single cell suspension treatment volume (>0.5 ml) and a single treatment cell throughput (>0.6×10 6 cells).
在一种或多种实施方式中,混悬体系挤出后继续孵育一段的时间,细胞经孵育后细胞膜孔和核膜孔修复,外源性材料能够保留在细胞质及细胞核中。In one or more embodiments, after the suspension system is extruded, the incubation is continued for a period of time, the cell membrane pores and nuclear membrane pores are repaired after the incubation, and the exogenous materials can be retained in the cytoplasm and nucleus.
在一种或多种实施方式中,所述方法还包括在继续培养经过挤出的细胞前,分离混悬体系中的外源物质,可选的采用离心的方法去除外源物质,然后将细胞继续培养。In one or more embodiments, the method further includes separating the exogenous substances in the suspension system before continuing to culture the extruded cells, optionally using a centrifugal method to remove the exogenous substances, and then removing the exogenous substances Continue to cultivate.
可以理解的是,本公开对外源物质的种类没有限制,本领域技术人员可以根据实际生产和研究的需要,采用本公开的方法将任意的外源物质递送进入任意的细胞。并且基于本公开提供的外源物质递送至细胞内的装置的有益效果,本公开的方法尤其适合将较大的分子递送至细胞质和细胞核内。It is understandable that the present disclosure does not limit the types of foreign substances, and those skilled in the art can use the methods of the present disclosure to deliver any foreign substances into any cell according to actual production and research needs. And based on the beneficial effects of the device for delivering foreign substances into cells provided by the present disclosure, the method of the present disclosure is particularly suitable for delivering larger molecules into the cytoplasm and nucleus.
本公开所述的外源物质,可以为来源于天然物质,包括但不限于天然来源的核酸、蛋白质或糖蛋白等;也可以来源于人工合成或改造的物质,包括但不限于大分子聚合物、人工合成核酸或纳米元器件等。所述外源物质还可以经修饰物修饰,包括但不限于使用荧光标记、同位素标记或药物修饰剂;在一种或多种实施方式中,所述外源物质包括荧光标记物修饰的核酸、同位素标记的蛋白质或药物修饰剂修饰的具有治疗作用的合成大分子等。The exogenous substances described in the present disclosure may be natural substances, including but not limited to nucleic acids, proteins or glycoproteins from natural sources; they may also be artificially synthesized or modified substances, including but not limited to macromolecular polymers , Artificial synthesis of nucleic acids or nano-components, etc. The exogenous substance can also be modified by a modifier, including but not limited to the use of fluorescent labels, isotope labels or drug modifiers; in one or more embodiments, the exogenous substance includes nucleic acids modified by fluorescent labels, Isotope-labeled protein or drug modifier modified synthetic macromolecules with therapeutic effects, etc.
可以理解的是,所述外源物质可以为单一种类的物质,也可以包括不同种类物质的组合,其中优选包括葡聚糖、DNA、RNA、蛋白质、核糖核蛋白复合体和纳米器件中的一种,或者几种的组合。例如外源物质包括DNA和核糖核蛋白复合体的混合物。例如外源物质包括DNA和蛋白质的混合物。例如外源物质包括葡聚糖、DNA和纳米器件的组合物。It is understandable that the foreign substance can be a single kind of substance or a combination of different kinds of substances, which preferably includes one of dextran, DNA, RNA, protein, ribonucleoprotein complex and nanodevice. Species, or a combination of several. For example, foreign substances include a mixture of DNA and ribonucleoprotein complexes. For example, foreign substances include a mixture of DNA and protein. For example, the foreign substance includes a combination of dextran, DNA, and nanodevices.
在一种或多种实施方式中,DNA包括生物来源的DNA或合成DNA。在一种或多种实施方式中,生物来源的DNA包括经生物合成扩增的DNA分子,包括但不限于从微生物中提取的质粒或从微生物或动物中直接提取的DNA分子等。在一种或多种实施方式中,合成DNA指的是不经生物作用合成的DNA分子,例如直接经化学合成的DNA分子。在一种或多种实施方式中,生物来源的DNA包括质粒,以将带有目的基因的质粒转化至细胞内,以上调或抑制目的蛋白的表达,或使细胞表达外源蛋白。在一种或多种实施方式中,RNA包括mRNA、siRNA、miRNA或lncRNA,以研究RNA类分子对真核细胞的调控作用。In one or more embodiments, DNA includes biologically derived DNA or synthetic DNA. In one or more embodiments, the biologically derived DNA includes DNA molecules amplified by biosynthesis, including but not limited to plasmids extracted from microorganisms or DNA molecules directly extracted from microorganisms or animals. In one or more embodiments, synthetic DNA refers to a DNA molecule synthesized without biological action, for example, a DNA molecule synthesized directly chemically. In one or more embodiments, the biologically derived DNA includes a plasmid to transform the plasmid with the target gene into the cell, up-regulate or inhibit the expression of the target protein, or allow the cell to express an exogenous protein. In one or more embodiments, RNA includes mRNA, siRNA, miRNA, or lncRNA to study the regulatory effect of RNA-based molecules on eukaryotic cells.
由于本公开提供的外源物质递送至真核细胞内的装置能将水合半径大于细胞核膜孔复合体(nuclear pore complex,NPC)扩散上限的外源物质递送入细胞核。因此,在一种或多种实施方式中,所述外源物质中至少一种不能通过自由扩散跨越细胞核膜核孔复合体的物质。Because the device for delivering exogenous substances into eukaryotic cells provided in the present disclosure can deliver exogenous substances with a hydration radius larger than the upper limit of the diffusion of the nuclear pore complex (NPC) into the nucleus. Therefore, in one or more embodiments, at least one of the exogenous substances cannot cross the nuclear membrane nuclear pore complex of the cell nuclear membrane by free diffusion.
在一种或多种实施方式中,所述不能通过自由扩散跨越细胞核膜核孔复合体的物质包括葡聚糖,所述葡聚糖的分子量至少为41kDa,例如70kDa~2MDa,诸如2MDa的葡聚糖。In one or more embodiments, the substance that cannot cross the nuclear membrane nuclear pore complex by free diffusion includes dextran, and the molecular weight of the dextran is at least 41kDa, for example 70kDa-2MDa, such as 2MDa dextran. Glycans.
在一种或多种实施方式中,所述不能通过自由扩散跨越细胞核膜核孔复合体的物质包括DNA,所述DNA的分子量至少为1k bp。In one or more embodiments, the substance that cannot cross the nuclear membrane nuclear pore complex by free diffusion includes DNA, and the molecular weight of the DNA is at least 1 kbp.
本公开不限制被递送外源物质的真核细胞的种类,可根据实际研发和生产需要向真核细胞中递送外源物质。在一种或多种实施方式中,被递送外源物质的真核细胞,例如来源于哺乳动物,所述哺乳动物包括但不限于人、猪、牛、猴、鼠或羊,例如人或鼠。所述真核细胞包括原代细胞或细胞株。原代细胞指的是直接从有机体中分离出的细胞,包括但不限于从血液、皮肤、骨骼、心脏或肌腱等动物的各种组织和器官中分离出的细胞,也可以包括这些原代细胞还未构成稳定细胞株的传代细胞。细胞株指的是具有稳定形状的传代细胞,这些传代细胞可以由原代细胞经稳定传代后得到,也可以来源于商品化的细胞系,包括但不限于CHO细胞、PK15细胞、Hela细胞、K562细胞或CT26细胞。The present disclosure does not limit the types of eukaryotic cells to which exogenous substances are delivered, and exogenous substances can be delivered to eukaryotic cells according to actual development and production needs. In one or more embodiments, the eukaryotic cells to which the exogenous substance is delivered are, for example, derived from mammals, including but not limited to humans, pigs, cows, monkeys, mice, or sheep, such as humans or mice. . The eukaryotic cells include primary cells or cell lines. Primary cells refer to cells isolated directly from organisms, including but not limited to cells isolated from various tissues and organs of animals such as blood, skin, bones, heart or tendons, and may also include these primary cells Passage cells that have not yet constituted a stable cell line. Cell lines refer to passage cells with a stable shape. These passage cells can be obtained from primary cells after stable passage, or they can be derived from commercial cell lines, including but not limited to CHO cells, PK15 cells, Hela cells, K562 Cells or CT26 cells.
在一种或多种实施方式中,所述原代细胞的种类包括但不限于干细胞、免疫细胞、肿瘤细胞、成纤维细胞、皮肤细胞或神经元,例如包括免疫细胞、肿瘤细胞或干细胞。在一种或多种实施方式中,免疫细胞包括T细胞、B细胞、DC细胞、NK细胞、单核细胞、肥大细胞、嗜酸性粒细胞、嗜碱性粒细胞、嗜中性粒细胞或巨噬细胞。在一种或多种实施方 式中,干细胞包括造血干细胞、间充质干细胞或皮肤干细胞。在一种或多种实施方式中,免疫细胞、肿瘤细胞或干细胞来源于哺乳动物,例如人或鼠。在一种或多种实施方式中,免疫细胞是人的免疫细胞,以更适用于常规的生产和科研需要。In one or more embodiments, the types of primary cells include, but are not limited to, stem cells, immune cells, tumor cells, fibroblasts, skin cells, or neurons, for example, immune cells, tumor cells, or stem cells. In one or more embodiments, immune cells include T cells, B cells, DC cells, NK cells, monocytes, mast cells, eosinophils, basophils, neutrophils, or giant cells. Phages. In one or more embodiments, the stem cells include hematopoietic stem cells, mesenchymal stem cells, or skin stem cells. In one or more embodiments, the immune cells, tumor cells or stem cells are derived from mammals, such as humans or mice. In one or more embodiments, the immune cells are human immune cells, which are more suitable for routine production and scientific research needs.
本公开还提供了上述装置或上述方法在调控细胞功能中的应用。本公开通过向真核细胞中递送外源物质以上调或下调真核细胞表达某些蛋白质,或使真核细胞表达外源蛋白质等本公开所述的调控可以为短暂调控,即使细胞在一段相对短的时间内改变生理生化特征,也可以为持续调控,即使细胞持续的改变生理生化特征。The present disclosure also provides the application of the above-mentioned device or the above-mentioned method in regulating cell function. The present disclosure up-regulates or down-regulates the expression of certain proteins by eukaryotic cells by delivering exogenous substances to eukaryotic cells, or allows eukaryotic cells to express foreign proteins. The regulation described in the present disclosure can be transient regulation, even if the cells are relatively Changing physiological and biochemical characteristics in a short period of time can also be continuous regulation, even if cells continue to change physiological and biochemical characteristics.
在一种或多种实施方式中,所述调控细胞功能包括短暂调控或持续调控。在一种或多种实施方式中,所述调控细胞功能包括下调或上调细胞中特定蛋白的表达。在一种或多种实施方式中,下调细胞中特定蛋白的表达包括下调程序性死亡受体-1、T细胞受体或主要组织相容性复合体的表达。在一种或多种实施方式中,所述调控细胞功能包括使细胞表达外源蛋白。在一种或多种实施方式中,所述外源蛋白包括嵌合抗原受体、识别特定抗原的T细胞受体和β球蛋白。上调、下调或使真核细胞表达外源蛋白可用于生产蛋白类药物,例如生产单克隆抗体、融合蛋白或疫苗用抗原等。In one or more embodiments, the regulation of cellular functions includes transient regulation or continuous regulation. In one or more embodiments, the regulating cell function includes down-regulating or up-regulating the expression of a specific protein in the cell. In one or more embodiments, down-regulating the expression of a specific protein in a cell includes down-regulating the expression of programmed death receptor-1, T cell receptor or major histocompatibility complex. In one or more embodiments, the regulation of cell functions includes allowing cells to express foreign proteins. In one or more embodiments, the foreign protein includes a chimeric antigen receptor, a T cell receptor that recognizes a specific antigen, and beta globulin. Up-regulation, down-regulation, or expression of foreign proteins by eukaryotic cells can be used to produce protein drugs, such as monoclonal antibodies, fusion proteins, or antigens for vaccines.
下面结合优选实施例进一步说明本公开的技术方案和有益效果。The technical solutions and beneficial effects of the present disclosure will be further described below in conjunction with preferred embodiments.
实施例1Example 1
本实施例提供了一种外源物质递送至真核细胞内的装置,该装置以PET核孔膜(购自中科院近代物理所(江碧透))作为微孔膜。PET核孔膜是将PET薄膜经高能重离子辐照形成直径约10nm的圆柱状管道,然后经化学蚀刻产生较大的特定直径孔道;以脂质体挤出仪LF1(加拿大AVESTIN公司)作为提供正压力的压力单元,将PET核孔膜置于脂质体挤出仪内,以组装成本实施例的外源物质递送至真核细胞内的装置。PET核孔膜如图2A和图2B所示,脂质体挤出仪LF1如图2C所示。This embodiment provides a device for delivering exogenous substances into eukaryotic cells. The device uses PET nuclear porous membrane (purchased from the Institute of Modern Physics, Chinese Academy of Sciences (Jiang Bitou)) as the microporous membrane. The PET nuclear pore membrane is a PET film that is irradiated with high-energy heavy ions to form a cylindrical pipe with a diameter of about 10 nm, and then chemically etched to produce a larger specific diameter pore; provided by liposome extruder LF1 (Canada AVESTIN Company) The positive pressure pressure unit puts the PET nuclear pore membrane in the liposome extruder to assemble the device for delivering exogenous substances into eukaryotic cells according to the embodiment. The PET nuclear porous membrane is shown in Figure 2A and Figure 2B, and the liposome extruder LF1 is shown in Figure 2C.
实施例2Example 2
本实施例提供了一种外源物质递送至真核细胞内的装置,如图3所示,其中图标110为微孔膜,120为活塞管体,130为活塞推杆。该装置以PET核孔膜(购自中科院近代物理所(江碧透))作为微孔膜110,该装置的挤出模块以活塞单元作为压力单元向真核细胞和外源物质施与正压力,具体的结构如下:This embodiment provides a device for delivering exogenous substances into eukaryotic cells, as shown in FIG. 3, where icon 110 is a microporous membrane, 120 is a piston tube body, and 130 is a piston push rod. The device uses PET nuclear porous membrane (purchased from the Institute of Modern Physics, Chinese Academy of Sciences (Jiang Bitou)) as the microporous membrane 110. The extrusion module of the device uses a piston unit as a pressure unit to apply positive pressure to eukaryotic cells and exogenous substances. , The specific structure is as follows:
所述活塞单元包括活塞管体120和活塞推杆130,活塞管体120和活塞推杆130可拆卸的滑动密封连接;在远离活塞推杆130进入一端的活塞管体120的底部设置可拆卸的PET核孔膜作为微孔膜110。使用时将真核细胞和外源物质的混悬体系置入活塞管体120内,将活塞推杆130插入活塞管体120内,推动活塞推杆130,使真核细胞和外源物质的混悬体系经分布于PET核孔膜上的孔道挤出,从PET核孔膜的另一侧流出并收集。The piston unit includes a piston tube body 120 and a piston push rod 130, the piston tube body 120 and the piston push rod 130 are detachably connected by sliding and sealing; a detachable piston tube body 120 is provided at the bottom of the piston tube body 120 that is far from the piston push rod 130 and enters one end. The PET nuclear porous film serves as the microporous film 110. When in use, the suspension system of eukaryotic cells and exogenous substances is placed in the piston tube 120, the piston push rod 130 is inserted into the piston tube 120, and the piston push rod 130 is pushed to mix the eukaryotic cells and the exogenous material. The suspension system is extruded through the channels distributed on the PET nuclear-porous membrane, and flows out from the other side of the PET nuclear-porous membrane and collected.
实施例3Example 3
本实施例提供了一种外源物质递送至真核细胞内的装置,如图4所示,其中图标110为微孔膜,120为活塞管体,130为活塞推杆,210为腔体,221为流入通路,222为流出通路。This embodiment provides a device for delivering exogenous substances into eukaryotic cells, as shown in Figure 4, where icon 110 is a microporous membrane, 120 is a piston tube, 130 is a piston push rod, and 210 is a cavity. 221 is the inflow passage, and 222 is the outflow passage.
该装置以PET核孔膜(购自中科院近代物理所(江碧透))作为微孔膜110,该装置的挤出模块以活塞单元作为压力单元向真核细胞和外源物质施与正压力,该装置以包括流体循环控温单元的温控模块控制温度,具体的结构如下:The device uses PET nuclear porous membrane (purchased from the Institute of Modern Physics, Chinese Academy of Sciences (Jiang Bitou)) as the microporous membrane 110. The extrusion module of the device uses a piston unit as a pressure unit to apply positive pressure to eukaryotic cells and exogenous substances. The device uses a temperature control module including a fluid circulation temperature control unit to control the temperature, and the specific structure is as follows:
所述活塞单元包括活塞管体120和活塞推杆130,活塞管体120和活塞推杆130可拆卸的滑动密封连接;在远离活塞推杆130进入一端的活塞管体120的底部设置可拆卸的PET核孔膜作为微孔膜110。所述活塞管体120的管壁外层设置有腔体210,腔体210用于流体循环控温单元中的流体流通,腔体210的外壁上设置有用于流体进入和流出的通路,本实施方式以靠近微孔膜110一端的通路为流入通路221,以靠近活塞推杆130进入一端的通路为流出通路222。腔体210上的两条通路与恒温水浴槽的外循环相连,使具有恒定温度的液体持续且稳定的从腔体210中流进和流出。The piston unit includes a piston tube body 120 and a piston push rod 130, the piston tube body 120 and the piston push rod 130 are detachably connected by sliding and sealing; a detachable piston tube body 120 is provided at the bottom of the piston tube body 120 that is far from the piston push rod 130 and enters one end. The PET nuclear porous film serves as the microporous film 110. The outer wall of the piston tube 120 is provided with a cavity 210, which is used for fluid circulation in the fluid circulation temperature control unit, and the outer wall of the cavity 210 is provided with passages for fluid to enter and flow out. In this way, the passage close to one end of the microporous membrane 110 is the inflow passage 221, and the passage close to the entry end of the piston push rod 130 is the outflow passage 222. The two passages on the cavity 210 are connected with the outer circulation of the constant temperature water bath, so that the liquid with a constant temperature can flow in and out of the cavity 210 continuously and stably.
使用时打开恒温水浴槽的外循环,设定恒温水浴槽的温度,使具有预设温度的液体持续的从腔体210中流过;然后将真核细胞和外源物质的混悬体系置入活塞管体120内,将活塞推杆130插入活塞管体120内,推动活塞推杆130,使真核细胞和外源物质的混悬体系经分布于PET核孔膜上的孔道挤出,从PET核孔膜的另一侧流出并收集。When in use, open the outer circulation of the constant temperature water bath, set the temperature of the constant temperature water bath, so that the liquid with the preset temperature flows continuously through the cavity 210; then the suspension system of eukaryotic cells and exogenous substances is placed in the piston In the tube body 120, insert the piston push rod 130 into the piston tube body 120 and push the piston push rod 130 so that the suspension system of eukaryotic cells and foreign substances is extruded through the channels distributed on the PET nuclear membrane. The other side of the nuclear pore membrane flows out and collects.
实施例4Example 4
将70kDa和2MDa葡聚糖递送到CT26(小鼠结肠癌细胞株)细胞质及细胞核。本实施例使用实施例1提供的装置。为了评估包含在PET核孔膜中的规则孔道介导的外源物质向细胞质和细胞核内的递送,将70kDa或2MDa FITC标记葡聚糖(FITC-dextran,以下简称葡聚糖)与CT26混合的细胞悬液穿过具有不同孔径孔道的PET核孔膜,用共聚焦显微镜和流式细胞仪分析评价细胞核内递送结果和细胞内递送效率。试验材料如表1所示:70kDa and 2MDa glucan were delivered to the cytoplasm and nucleus of CT26 (mouse colon cancer cell line). This embodiment uses the device provided in Embodiment 1. In order to evaluate the delivery of exogenous substances to the cytoplasm and nucleus mediated by regular pores contained in the PET nuclear membrane, 70kDa or 2MDa FITC-labeled dextran (FITC-dextran, hereinafter referred to as dextran) mixed with CT26 The cell suspension was passed through PET nuclear pore membranes with different pore diameter channels, and the results of intranuclear delivery and intracellular delivery efficiency were evaluated by confocal microscope and flow cytometry. The test materials are shown in Table 1:
表1递送试验的主要耗材Table 1 Main consumables for delivery test
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
70kDa FITC-dextran(葡聚糖)70kDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
2MDa FITC-dextran(葡聚糖)2MDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
Hoechst33342Hoechst33342 美国Sigma-Aldrich公司American Sigma-Aldrich Company
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
共聚焦皿Confocal dish 无锡耐思生物科技有限公司Wuxi Nice Biotechnology Co., Ltd.
CT26细胞株CT26 cell line 北京协和细胞库Beijing Concord Cell Bank
待CT26细胞生长至融合度80%左右,弃掉旧培养基,用PBS冲洗2遍,加入胰酶,待显微镜下观察到大量细胞变圆后,再加入RPMI 1640完全培养基终止消化,轻轻晃动培养皿并用移液器轻轻吹打细胞使其成为单细胞悬液(细胞浓度1.2×10 6个细胞/毫升),然后室温下(25℃)加入70kDa或2MDa葡聚糖,混匀后将0.5mL细胞悬液转入实施例1提供的装置,用脂质体挤出仪推动细胞悬液穿过PET核孔膜的规则孔道。 When CT26 cells grow to about 80% confluency, discard the old medium, wash twice with PBS, add trypsin, and when a large number of cells are rounded under the microscope, add RPMI 1640 complete medium to stop the digestion, gently Shake the petri dish and gently pipette the cells to form a single cell suspension (cell concentration 1.2×10 6 cells/ml), then add 70kDa or 2MDa dextran at room temperature (25°C), mix well 0.5 mL of the cell suspension was transferred to the device provided in Example 1, and the liposome extruder was used to push the cell suspension through the regular pores of the PET nuclear pore membrane.
收集处理后的细胞悬液,孵育一定时间,然后离心弃去上清,细胞培养基重悬细胞继续培养24小时。培养结束,加入Hoechst33342溶液,孵育15分钟后弃去上清,用PBS冲洗2次,再加入20μL PBS,用共聚焦显微镜的油镜(630×)观察并拍照。并且收集处理后的细胞悬液,孵育一定时间,离心弃去上清,PBS重悬细胞并清洗2次,重悬于PBS中的细胞用流式细胞仪分析递送效率。Collect the processed cell suspension, incubate for a certain period of time, then centrifuge to discard the supernatant, resuspend the cells in the cell culture medium and continue culturing for 24 hours. After incubation, add Hoechst33342 solution, incubate for 15 minutes, discard the supernatant, wash twice with PBS, add 20μL PBS, observe and take pictures with the oil lens (630×) of a confocal microscope. And collect the processed cell suspension, incubate for a certain period of time, centrifuge to discard the supernatant, resuspend the cells in PBS and wash twice, and analyze the delivery efficiency of the cells resuspended in PBS with a flow cytometer.
试验结果:test results:
共聚焦扫描显微镜观察70kDa和2MDa葡聚糖在CT26细胞质和细胞核的分布,实验结果如图5A和5B显示了70kDa和2MDa葡聚糖在CT26细胞的亚细胞分布,可见2种葡聚糖不仅递送到了细胞质,而且递送到细胞核。Confocal scanning microscope observed the distribution of 70kDa and 2MDa glucan in CT26 cytoplasm and nucleus. The experimental results shown in Figure 5A and 5B show the subcellular distribution of 70kDa and 2MDa glucan in CT26 cells. It can be seen that the two kinds of glucans not only deliver To the cytoplasm, and delivered to the nucleus.
流式细胞仪分析葡聚糖在CT26的细胞内递送效率如图6A和图6B所示,显示了70kDa和2MDa葡聚糖的细胞内递送效率,以及递送效率与PET核孔膜孔直径的关系,在8微米孔直径条件下,70kDa和2MDa葡聚糖都获得了最高的细胞内递送效率。Flow cytometry analysis of the intracellular delivery efficiency of dextran in CT26 is shown in Figure 6A and Figure 6B, showing the intracellular delivery efficiency of 70kDa and 2MDa dextran, and the relationship between delivery efficiency and PET nuclear pore membrane pore diameter Under the condition of 8 micron pore diameter, both 70kDa and 2MDa glucan achieved the highest intracellular delivery efficiency.
实施例5Example 5
将70kDa和2MDa葡聚糖递送到K562细胞。为了评估包含在PET核孔膜中的规则孔道介导的外源性材料向细胞内的递送,将70kDa或2MDa FITC标记葡聚糖与K562细胞混合的悬液穿过实施例1提供的装置,用流式细胞仪分析评价细胞内递送效率。试验材料如表2所示:Delivery of 70kDa and 2MDa dextran to K562 cells. In order to evaluate the delivery of exogenous materials into cells mediated by regular pores contained in the PET nuclear membrane, a suspension of 70kDa or 2MDa FITC-labeled dextran mixed with K562 cells was passed through the device provided in Example 1. The intracellular delivery efficiency was evaluated by flow cytometry analysis. The test materials are shown in Table 2:
表2递送试验的主要耗材Table 2 Main consumables for delivery test
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
70kDa FITC-dextran(葡聚糖)70kDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
2MDa FITC-dextran(葡聚糖)2MDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
K562细胞株K562 cell line 北京协和细胞库Beijing Concord Cell Bank
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
取K562单细胞悬液离心,加入无血清培养基重悬细胞(细胞浓度1.2×10 6个细胞/毫升),然后加入70kDa或2MDa葡聚糖;不同孔径核孔膜安装在脂质体挤出仪LF1中,室温下(25摄氏度)把K562细胞和葡聚糖混悬液1毫升转入实施例1提供的装置,然后用脂质体挤出仪推动细胞悬液穿过PET核孔膜的规则孔道,收集处理后的细胞悬液,孵育一定时间,然后进行细胞计数(胎盼蓝染色);孵育完毕细胞样品离心弃去上清,PBS重悬细胞并清洗2次,重悬于PBS中的细胞用流式细胞仪分析递送效率。 Centrifuge the K562 single cell suspension, add serum-free medium to resuspend the cells (cell concentration 1.2×10 6 cells/ml), and then add 70kDa or 2MDa dextran; nuclear pore membranes of different pore sizes are installed in the liposome for extrusion In the instrument LF1, transfer 1 ml of the K562 cell and dextran suspension into the device provided in Example 1 at room temperature (25 degrees Celsius), and then use the liposome extruder to push the cell suspension through the PET nuclear pore membrane. Collect the processed cell suspension in a regular channel, incubate for a certain period of time, and then count the cells (fetal pan blue staining); after the incubation, the cell sample is centrifuged to discard the supernatant, the cells are resuspended in PBS and washed twice, and resuspended in PBS Of cells were analyzed by flow cytometry for delivery efficiency.
试验结果:test results:
流式细胞仪分析葡聚糖在K562的细胞内递送效率,流式细胞仪分析葡聚糖在K562的细胞内递送效率如图7A和图7B所示,显示了70kDa和2MDa葡聚糖的细胞内递送效率,以及递送效率与PET核孔膜孔直径的关系,在7微米孔直径条件下,70kDa和2MDa都获得了最高的细胞内递送效率。Flow cytometry analysis of the intracellular delivery efficiency of dextran in K562, flow cytometry analysis of the intracellular delivery efficiency of dextran in K562, as shown in Figure 7A and Figure 7B, showing cells of 70kDa and 2MDa dextran Internal delivery efficiency, and the relationship between delivery efficiency and PET nuclear pore membrane pore diameter, under the condition of 7 micron pore diameter, both 70kDa and 2MDa achieved the highest intracellular delivery efficiency.
此外,如图7C所示,在7、8和9微米孔径的条件下,细胞回收率在70-80%之间;而在10微米孔径的条件下,细胞回收率达到90%左右。细胞回收率数据显示随着核孔膜孔径的下降,细胞回收率也降低。综合孔径与递送效率和细胞回收率的关系,可以发现,降低孔径能增强递送效率,但是也会导致细胞回收率下降。因此,递送试验需要在保持一定的细胞回收率前提下,通过优化孔径尽量提高递送效率。In addition, as shown in FIG. 7C, the cell recovery rate is between 70-80% under the conditions of 7, 8 and 9 micron pore size; while under the condition of 10 micron pore size, the cell recovery rate reaches about 90%. The cell recovery rate data shows that as the pore size of the nuclear pore membrane decreases, the cell recovery rate also decreases. Comprehensive pore size, delivery efficiency and cell recovery rate, it can be found that reducing the pore size can enhance the delivery efficiency, but will also lead to a decline in cell recovery rate. Therefore, the delivery test needs to maximize the delivery efficiency by optimizing the pore size while maintaining a certain cell recovery rate.
实施例6Example 6
将pCMV-GFP质粒递送到K562细胞核并表达GFP蛋白。为了评估包含在PET核孔膜中的规则孔道介导的外源性材料向细胞质和细胞核内的递送,使用实施例3提供的装置将pCMV-GFP质粒(Plasmid#11153,4.4kbp)与K562细胞混合的悬液穿过微孔膜110,然后用共聚焦显微镜检测K562细胞的绿色荧光蛋白GFP表达,或用流式细胞仪分析K562的GFP表达水平。试验材料如表3所示:The pCMV-GFP plasmid was delivered to the nucleus of K562 cells and expressed the GFP protein. In order to evaluate the delivery of exogenous materials to the cytoplasm and nucleus mediated by regular pores contained in the PET nuclear pore membrane, the pCMV-GFP plasmid (Plasmid#11153, 4.4kbp) was combined with K562 cells using the device provided in Example 3. The mixed suspension is passed through the microporous membrane 110, and then the green fluorescent protein GFP expression of K562 cells is detected by a confocal microscope, or the GFP expression level of K562 is analyzed by a flow cytometer. The test materials are shown in Table 3:
表3递送试验的主要耗材Table 3 Main consumables for delivery test
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
K562细胞株K562 cell line 北京协和细胞库Beijing Concord Cell Bank
共聚焦皿Confocal dish 无锡耐思生物科技有限公司Wuxi Nice Biotechnology Co., Ltd.
取K562单细胞悬液离心,无血清培养基重悬细胞(细胞浓度1.2×10 6个细胞/毫升),然后加入pCMV-GFP质粒;使用PET核孔膜为7μm的实施例3提供的装置,在30℃条件下,把K562细胞和质粒混合物2mL转入装置中,用活塞推杆130推动细胞悬液穿过PET核孔膜的规则孔道,收集处理后的细胞悬液,孵育一定时间,离心弃去上清,用含血清培养基重悬细胞并继续培养2小时,共聚焦显微镜观察绿色荧光蛋白GFP的表达;或继续培养48小时,用流式细胞仪分析绿色荧光蛋白GFP的表达。 Centrifuge the K562 single cell suspension, resuspend the cells in serum-free medium (cell concentration 1.2×10 6 cells/ml), and then add pCMV-GFP plasmid; use the device provided in Example 3 with a PET nuclear pore membrane of 7 μm, At 30℃, transfer 2 mL of K562 cell and plasmid mixture into the device, use piston push rod 130 to push the cell suspension through the regular channels of PET nuclear membrane, collect the processed cell suspension, incubate for a certain time, and centrifuge Discard the supernatant, resuspend the cells in serum-containing medium and continue to culture for 2 hours, observe the expression of green fluorescent protein GFP with a confocal microscope; or continue to culture for 48 hours, analyze the expression of green fluorescent protein GFP with a flow cytometer.
试验结果:test results:
CLSM观察pCMV-GFP质粒在K562的表达。如图8所示,在K562和pCMV-GFP质粒混合悬液经实施例3提供的装置挤出后2小时,GFP开始表达,说明pCMV-GFP质粒递送进入了K562细胞核,并转录为编码GFP的mRNA,最后在核外周核糖体表达了GFP蛋白。CLSM observed the expression of pCMV-GFP plasmid in K562. As shown in Figure 8, 2 hours after the K562 and pCMV-GFP plasmid mixed suspension was extruded by the device provided in Example 3, GFP began to express, indicating that the pCMV-GFP plasmid was delivered into the K562 cell nucleus and transcribed into GFP-encoding mRNA, and finally the GFP protein is expressed in the nuclear ribosomes.
流式细胞术分析pCMV-GFP质粒在K562的表达。如图9所示,在K562和pCMV-GFP质粒混合悬液经实施例3提供的装置挤出后24小时,GFP表达阳性率达49%,说明pCMV-GFP质粒递送进入了较大比例的K562细胞核,并表达出GFP蛋白。The expression of pCMV-GFP plasmid in K562 was analyzed by flow cytometry. As shown in Figure 9, 24 hours after the K562 and pCMV-GFP plasmid mixed suspension was extruded by the device provided in Example 3, the positive rate of GFP expression reached 49%, indicating that the delivery of pCMV-GFP plasmid into a larger proportion of K562 Cell nucleus, and express GFP protein.
实施例7Example 7
将pCMV-GFP质粒(Plasmid#11153,4.4kbp)递送到CT26细胞核并表达GFP蛋白。为了评估包含在PET核孔膜中的规则孔道介导的外源性材料向细胞质和细胞核内的递送,将pCMV-GFP质粒与CT26单细胞悬液2mL使用实施例3提供的装置挤出,然后用流式细胞仪分析48小时CT26的GFP表达水平。试验材料如表4所示:The pCMV-GFP plasmid (Plasmid#11153, 4.4kbp) was delivered to the nucleus of CT26 cells and expressed the GFP protein. In order to evaluate the delivery of exogenous materials to the cytoplasm and nucleus mediated by regular pores contained in the PET nuclear pore membrane, 2 mL of the pCMV-GFP plasmid and CT26 single cell suspension were extruded using the device provided in Example 3. The GFP expression level of CT26 at 48 hours was analyzed by flow cytometry. The test materials are shown in Table 4:
表4递送试验的主要耗材Table 4 Main consumables for delivery test
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
CT26细胞株CT26 cell line 北京协和细胞库Beijing Concord Cell Bank
胰酶消化CT26细胞并用PBS清洗1次,离心,无血清培养基重悬细胞(细胞浓度1.2×10 6个细胞/毫升),然后加入pCMV-GFP质粒;使用PET核孔膜为8μm的实施例3提供的装置,30℃条件下把CT26细胞和质粒混合物2mL转入装置,然后用活塞推杆130推动细胞悬液穿过PET核孔膜的规则孔道,收集处理后的细胞悬液,孵育一定时间,离心弃去上清,用含血清培养基重悬细胞并继续培养48小时,用流式细胞仪分析绿色荧光蛋白GFP的表达。 Trypsin digest CT26 cells and wash them with PBS once, centrifuge, resuspend the cells in serum-free medium (cell concentration 1.2×10 6 cells/ml), and then add pCMV-GFP plasmid; use PET nuclear pore membrane with 8μm example 3 With the provided device, transfer 2 mL of CT26 cell and plasmid mixture into the device at 30°C, then use the plunger 130 to push the cell suspension through the regular channels of the PET nuclear membrane, collect the processed cell suspension, and incubate it for a certain amount After time, the supernatant was discarded by centrifugation, the cells were resuspended in serum-containing medium and cultured for 48 hours, and the expression of green fluorescent protein GFP was analyzed by flow cytometry.
流式细胞术分析pCMV-GFP质粒在CT26的表达,实验结果如图10所示:在CT26单细胞和pCMV-GFP质粒混合悬液穿过实施例3提供的装置后24小时,GFP表达阳性率达57.7%,说明pCMV-GFP质粒递送进入了较大比例的CT26细胞核,并表达出GFP蛋白。The expression of pCMV-GFP plasmid in CT26 was analyzed by flow cytometry. The experimental results are shown in Figure 10: 24 hours after the mixed suspension of CT26 single cells and pCMV-GFP plasmid passed through the device provided in Example 3, the positive rate of GFP expression It reached 57.7%, indicating that the pCMV-GFP plasmid was delivered into a larger proportion of CT26 cell nuclei and expressed GFP protein.
实施例8Example 8
2MDa葡聚糖递送入K562细胞质及细胞核。为了评估包含在PET核孔膜中的规则孔道介导的外源性材料向细胞质和细胞核内的递送,将2MDa FITC标记葡聚糖与K562细胞混合的悬液使用实施例3提供的装置挤出,用共聚焦显微镜评估葡聚糖在细胞质和细胞核的分布。试验材料如表5所示:2MDa glucan is delivered into K562 cytoplasm and nucleus. In order to evaluate the delivery of exogenous materials to the cytoplasm and the nucleus mediated by the regular pores contained in the PET nuclear membrane, a suspension of 2MDa FITC-labeled dextran mixed with K562 cells was extruded using the device provided in Example 3. , Use a confocal microscope to evaluate the distribution of dextran in the cytoplasm and nucleus. The test materials are shown in Table 5:
表5递送试验的主要耗材Table 5 Main consumables for delivery test
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
2MDa FITC-dextran(葡聚糖)2MDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
Hoechst33342Hoechst33342 美国Sigma-Aldrich公司American Sigma-Aldrich Company
K562细胞株K562 cell line 北京协和细胞库Beijing Concord Cell Bank
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
取K562单细胞悬液离心,加入无血清培养基重悬细胞(细胞浓度1.2×10 6个细胞/毫升),然后加入2MDa葡聚糖;将核孔膜安装在带有温度控制附件的装置中,30℃下,把K562细胞和葡聚糖混悬液2mL转入装置,然后用活塞推杆130推动细胞悬液穿过PET核孔膜的 规则孔道,收集处理后的细胞悬液,加入Hoechst33342细胞核染料,孵育一定时间,离心弃去上清,无血清培养基重悬细胞并清洗2次,再重悬于无血清培养基中并滴加在共聚焦皿,用共聚焦显微镜观察2MDa葡聚糖在细胞质和细胞核的分布。 Centrifuge the K562 single cell suspension, add serum-free medium to resuspend the cells (cell concentration 1.2×10 6 cells/ml), then add 2MDa dextran; install the nuclear pore membrane in a device with temperature control accessories At 30℃, transfer 2 mL of K562 cell and dextran suspension into the device, and then use the plunger 130 to push the cell suspension through the regular channels of the PET nuclear membrane, collect the processed cell suspension, and add Hoechst 33342 Cell nuclear dye, incubate for a certain time, centrifuge to discard the supernatant, resuspend the cells in serum-free medium and wash twice, then resuspend in serum-free medium and add dropwise to a confocal dish, observe 2MDa dextran with a confocal microscope The distribution of sugar in the cytoplasm and nucleus.
实验结果如图11所示,显示了2MDa葡聚糖的细胞内分布,可见经实施例3提供的装置挤出后,2MDa葡聚糖递送进入了K562细胞质和细胞核。The experimental results are shown in Figure 11, showing the intracellular distribution of 2MDa glucan. It can be seen that after extrusion by the device provided in Example 3, the 2MDa glucan was delivered into the K562 cytoplasm and nucleus.
实施例9Example 9
将2MDa葡聚糖递送到CT26(小鼠结肠癌细胞株)细胞。本实施例使用实施例3提供的装置。为了评估包含在薄膜中的规则孔道介导的外源物质向细胞质和细胞核内的递送,将2MDa葡聚糖与CT26混合的细胞悬液在4摄氏度下穿过9微米孔径孔道的PET核孔膜,用流式细胞仪分析评价细胞内递送效率。试验材料如表6所示:The 2MDa dextran was delivered to CT26 (mouse colon cancer cell line) cells. This embodiment uses the device provided in Embodiment 3. In order to evaluate the delivery of exogenous substances to the cytoplasm and nucleus mediated by the regular pores contained in the film, a cell suspension mixed with 2MDa dextran and CT26 was passed through a PET nuclear pore membrane with 9 micron pores at 4 degrees Celsius. , Use flow cytometry analysis to evaluate intracellular delivery efficiency. The test materials are shown in Table 6:
表6递送试验的主要耗材Table 6 Main consumables for delivery test
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
2MDa FITC-dextran(葡聚糖)2MDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
CT26细胞株CT26 cell line 北京协和细胞库Beijing Concord Cell Bank
待CT26细胞生长至融合度80%左右,弃掉旧培养基,用PBS冲洗2遍,加入1mL胰酶,待显微镜下观察到大量细胞变圆后,再加入2ml RPMI 1640完全培养基终止消化,轻轻晃动培养皿并用移液器轻轻吹打细胞使其成为单细胞悬液(细胞浓度1.2×10 6个细胞/毫升),然后加入2MDa葡聚糖,将装置温度预设为4摄氏度,混匀后将2mL细胞悬液转入实施例3提供的装置,用活塞推杆130推动细胞悬液穿过PET核孔膜的规则孔道。 After CT26 cells grow to about 80% confluency, discard the old medium, wash twice with PBS, add 1 mL of trypsin, and when a large number of cells are rounded under the microscope, add 2 ml of RPMI 1640 complete medium to stop the digestion. Gently shake the petri dish and pipette gently to make the cells become a single cell suspension (cell concentration 1.2×10 6 cells/ml), then add 2MDa dextran, set the device temperature to 4 degrees Celsius, mix After homogenization, 2 mL of the cell suspension was transferred to the device provided in Example 3, and the piston push rod 130 was used to push the cell suspension through the regular pores of the PET nuclear membrane.
收集处理后的细胞悬液,孵育一定时间,然后离心弃去上清,PBS重悬细胞并清洗2次,重悬于PBS中的细胞用流式细胞仪分析递送效率。Collect the treated cell suspension, incubate for a certain period of time, then centrifuge to discard the supernatant, resuspend the cells in PBS and wash twice, and analyze the delivery efficiency of the cells resuspended in PBS with a flow cytometer.
试验结果:test results:
流式细胞仪分析葡聚糖在CT26的细胞内递送效率如图12所示,显示了2MDa葡聚糖在4摄氏度和9微米孔径核孔膜条件下细胞内递送效率为39.3%。Flow cytometry analysis of the intracellular delivery efficiency of dextran in CT26 is shown in Figure 12, which shows that the delivery efficiency of 2MDa dextran at 4 degrees Celsius and 9 micron pore nuclear membrane conditions is 39.3%.
实施例10Example 10
CT26细胞密度影响挤出处理后的细胞回收率。为了评估细胞密度对挤出处理后细胞回收率的影响,将不同细胞密度的CT26细胞悬液使用实施例3提供的装置挤出,收集细胞并用Invitrogen Countess II细胞计数仪进行细胞计数和细胞存活率检测。The cell density of CT26 affects the cell recovery rate after extrusion. In order to evaluate the effect of cell density on the cell recovery rate after extrusion, CT26 cell suspensions with different cell densities were extruded using the device provided in Example 3. The cells were collected and the Invitrogen Countess II cell counter was used for cell counting and cell viability Detection.
表7试验的主要耗材Table 7 The main consumables tested
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
2MDa FITC-dextran(葡聚糖)2MDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
CT26细胞株CT26 cell line 北京协和细胞库Beijing Concord Cell Bank
细胞计数板Cell counting plate Invitrogen Countess细胞计数板Invitrogen Countess cell counting plate
待CT26细胞生长至融合度80%左右,弃掉旧培养基,用PBS冲洗2遍,加入胰酶,待显微镜下观察到大量细胞变圆后,再加入RPMI 1640完全培养基终止消化,轻轻晃动培养皿并用移液器轻轻吹打细胞使其成为单细胞悬液,分别制备成不同细胞浓度(1、2、4、8×10 6个细胞/毫升)的的细胞悬液,室温下2MDa葡聚糖,混匀后将2mL细胞悬液转入实 施例3提供的装置(8μm PET核孔膜),用活塞推动细胞悬液穿过PET核孔膜的规则孔道。收集处理后的细胞悬液,孵育一定时间,然后进行细胞计数(胎盼蓝染色)。 When CT26 cells grow to about 80% confluency, discard the old medium, wash twice with PBS, add trypsin, and when a large number of cells are rounded under the microscope, add RPMI 1640 complete medium to stop the digestion, gently Shake the petri dish and gently pipette the cells into a single cell suspension. Prepare cell suspensions with different cell concentrations (1, 2, 4, 8×10 6 cells/ml), 2MDa at room temperature After mixing the dextran, 2 mL of the cell suspension was transferred to the device provided in Example 3 (8 μm PET nuclear pore membrane), and the piston was used to push the cell suspension through the regular pores of the PET nuclear pore membrane. Collect the processed cell suspension, incubate for a certain period of time, and then perform cell counting (fetopan blue staining).
细胞回收率=(收集细胞样本中的活细胞数/处理前细胞悬液中活细胞数)×100%Cell recovery rate = (the number of living cells in the collected cell sample/the number of living cells in the cell suspension before treatment)×100%
细胞回收率数据如图13,显示细胞浓度越高,细胞回收率越低。细胞浓度在1×10 6个/毫升和2×10 6个/毫升条件下的细胞回收率大于80%。为了将外源物质高效递送至真核细胞,需要选择合适的细胞浓度范围,以确保获得较高的细胞回收率。 The cell recovery rate data is shown in Figure 13, showing that the higher the cell concentration, the lower the cell recovery rate. The cell recovery rate under the conditions of 1×10 6 cells/ml and 2×10 6 cells/ml is greater than 80%. In order to efficiently deliver exogenous substances to eukaryotic cells, a suitable cell concentration range needs to be selected to ensure a high cell recovery rate.
实施例11Example 11
外源物质分子量影响细胞内递送效率。将70kDa和2MDa葡聚糖递送到K562细胞。为了评估外源性材料分子量对细胞内递送效率的影响,将70kDa或2MDa FITC标记葡聚糖与K562细胞混合的悬液穿过实施例1提供的装置,用流式细胞仪分析评价细胞内递送效率。试验材料如表8所示:The molecular weight of foreign substances affects the efficiency of intracellular delivery. Delivery of 70kDa and 2MDa dextran to K562 cells. In order to evaluate the influence of the molecular weight of exogenous materials on the intracellular delivery efficiency, a suspension of 70kDa or 2MDa FITC-labeled dextran mixed with K562 cells was passed through the device provided in Example 1, and the intracellular delivery was analyzed by flow cytometry. effectiveness. The test materials are shown in Table 8:
表8递送试验的主要耗材Table 8 Main consumables for delivery test
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
70kDa FITC-dextran(葡聚糖)70kDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
2MDa FITC-dextran(葡聚糖)2MDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
K562细胞株K562 cell line 北京协和细胞库Beijing Concord Cell Bank
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
取K562单细胞悬液离心,加入无血清培养基重悬细胞(细胞浓度1.2×10 6个细胞/毫升),然后加入70kDa或2MDa葡聚糖;不同孔径核孔膜安装在脂质体挤出仪LF1中,室温下(25摄氏度)把K562细胞和葡聚糖混悬液1毫升转入实施例1提供的装置,然后用脂质体挤出仪推动细胞悬液穿过PET核孔膜的规则孔道,收集处理后的细胞悬液,孵育一定时间,离心弃去上清,PBS重悬细胞并清洗2次,重悬于PBS中的细胞用流式细胞仪分析递送效率。 Centrifuge the K562 single cell suspension, add serum-free medium to resuspend the cells (cell concentration 1.2×10 6 cells/ml), and then add 70kDa or 2MDa dextran; nuclear pore membranes of different pore sizes are installed in the liposome for extrusion In the instrument LF1, transfer 1 ml of the K562 cell and dextran suspension into the device provided in Example 1 at room temperature (25 degrees Celsius), and then use the liposome extruder to push the cell suspension through the PET nuclear pore membrane. Collect the processed cell suspension in regular channels, incubate for a certain period of time, centrifuge to discard the supernatant, resuspend the cells in PBS and wash twice, and analyze the delivery efficiency of the cells resuspended in PBS by flow cytometry.
试验结果:流式细胞仪分析葡聚糖在K562的细胞内递送效率如图14所示,显示了70kDa和2MDa葡聚糖的细胞内递送效率,以及葡聚糖分子量与递送效率的关系。在4种孔径的PET核孔膜条件下(7μm、8μm、9μm、10μm),2MDa葡聚糖的细胞内递送效率(FITC阳性率,MFI平均荧光强度)都小于70kDa葡聚糖,说明外源物质分子量越大,细胞内递送效率越低。Test results: Flow cytometry analysis of the intracellular delivery efficiency of dextran in K562 is shown in Figure 14, showing the intracellular delivery efficiency of 70kDa and 2MDa dextran, as well as the relationship between dextran molecular weight and delivery efficiency. Under the conditions of 4 kinds of pores of PET nuclear membrane (7μm, 8μm, 9μm, 10μm), the intracellular delivery efficiency of 2MDa glucan (FITC positive rate, MFI average fluorescence intensity) is less than 70kDa glucan, indicating exogenous The higher the molecular weight of the substance, the lower the efficiency of intracellular delivery.
实施例12Example 12
温度影响细胞内递送效率和质粒转染效率。在不同温度条件下,将2MDa葡聚糖递送到CT26(小鼠结肠癌细胞株)细胞。本实施例使用实施例3提供的装置。为了评估温度对外源物质向细胞内递送效率和细胞回收率的影响,将2MDa FITC标记葡聚糖(FITC-dextran,以下简称葡聚糖)或pCMV-GFP质粒DNA与CT26混合的细胞悬液穿过具有8μm孔径孔道的PET核孔膜,用细胞计数仪检测细胞回收率,并用流式细胞仪分析细胞内递送效率。葡聚糖递送试验在5个温度条件下(15℃、20℃、25℃、30℃、35℃)进行,质粒转染试验在2个温度条件下(25℃、30℃)进行。试验材料如表9所示:Temperature affects intracellular delivery efficiency and plasmid transfection efficiency. Under different temperature conditions, 2MDa dextran was delivered to CT26 (mouse colon cancer cell line) cells. This embodiment uses the device provided in Embodiment 3. In order to evaluate the effect of temperature on the delivery efficiency of foreign substances into cells and cell recovery rate, 2MDa FITC-labeled dextran (FITC-dextran, hereinafter referred to as dextran) or pCMV-GFP plasmid DNA mixed with CT26 cell suspension was passed through Pass the PET nuclear pore membrane with 8 μm pores, use a cell counter to detect the cell recovery rate, and use a flow cytometer to analyze the intracellular delivery efficiency. The dextran delivery test was performed under 5 temperature conditions (15°C, 20°C, 25°C, 30°C, 35°C), and the plasmid transfection test was performed under two temperature conditions (25°C, 30°C). The test materials are shown in Table 9:
表9试验的主要耗材Table 9 The main consumables tested
耗材Supplies 来源source
RPMI1640培养基RPMI1640 medium 美国GE healthcare公司United States GE Healthcare
胎牛血清FBSFetal Bovine Serum FBS 以色列Biological Industries公司Israel Biological Industries Company
2MDa FITC-dextran(葡聚糖)2MDa FITC-dextran (dextran) 美国Sigma-Aldrich公司American Sigma-Aldrich Company
胰酶-EDTAPancreatin-EDTA 美国Invitrogen公司American Invitrogen Company
CT26细胞株CT26 cell line 北京协和细胞库Beijing Concord Cell Bank
待CT26细胞生长至融合度80%左右,弃掉旧培养基,用PBS冲洗2遍,加入胰酶,待显微镜下观察到大量细胞变圆后,再加入RPMI 1640完全培养基终止消化,轻轻晃动培养皿并用移液器轻轻吹打细胞使其成为单细胞悬液,然后加入2MDa葡聚糖或质粒DNA,混匀,不同温度下将2mL细胞悬液转入实施例3提供的装置,用活塞杆推动细胞悬液穿过PET核孔膜的规则孔道。When CT26 cells grow to about 80% confluency, discard the old medium, rinse with PBS twice, add trypsin, and when a large number of cells are rounded under the microscope, add RPMI 1640 complete medium to stop the digestion, gently Shake the culture dish and gently pipette the cells into a single cell suspension, then add 2MDa dextran or plasmid DNA, mix well, and transfer 2 mL of the cell suspension to the device provided in Example 3 at different temperatures. The piston rod pushes the cell suspension through the regular pores of the PET nuclear membrane.
收集处理后的细胞悬液,孵育一定时间,取样进行细胞计数检测,然后离心弃去上清,PBS重悬细胞并清洗2次,重悬于PBS中的细胞用流式细胞仪分析递送效率。对于质粒DNA转染试验,收集处理后的细胞悬液,孵育一定时间,离心弃去上清,用含FBS的RPMI1640培养基重悬,培养48h,胰酶消化细胞,制备成单细胞悬液,流式细胞仪检测GFP表达。Collect the processed cell suspension, incubate for a certain period of time, take samples for cell count detection, then centrifuge to discard the supernatant, resuspend the cells in PBS and wash twice, and analyze the delivery efficiency of the cells resuspended in PBS by flow cytometry. For plasmid DNA transfection experiments, collect the processed cell suspension, incubate for a certain period of time, centrifuge to discard the supernatant, resuspend in RPMI1640 medium containing FBS, culture for 48 hours, trypsinize the cells to prepare a single cell suspension, Flow cytometry was used to detect GFP expression.
试验结果:test results:
葡聚糖在CT26的细胞内递送效率和细胞回收率如图15所示,显示温度影响2MDa葡聚糖的细胞内递送效率和细胞回收率,在8微米孔径条件下,随着温度的增加,细胞回收率增加,而2MDa葡聚糖在30℃条件下获得了最高的细胞内递送效率,说明在所设定的5个温度条件下,30℃是最佳递送条件,既能获得最高的细胞内递送效率,也能获得优化的细胞回收率。The intracellular delivery efficiency and cell recovery rate of dextran in CT26 are shown in Figure 15, showing that temperature affects the intracellular delivery efficiency and cell recovery rate of 2MDa dextran. Under the condition of 8 micron pore size, as the temperature increases, The cell recovery rate increased, and 2MDa glucan achieved the highest intracellular delivery efficiency at 30°C, indicating that 30°C is the best delivery condition under the set 5 temperature conditions, which can obtain the highest cells. The internal delivery efficiency can also obtain an optimized cell recovery rate.
如图16所示,在所设定的2个温度条件下的CT26转染试验,30℃下CT26具有更高的GFP表达水平(GFP阳性率和GFP表达的平均荧光强度MFI),说明相比于25℃,30℃下具有更好的转染效果。As shown in Figure 16, in the CT26 transfection test under the set 2 temperature conditions, CT26 has a higher GFP expression level (GFP positive rate and the average fluorescence intensity MFI of GFP expression) at 30°C, indicating the comparison It has better transfection effect at 25℃ and 30℃.
实施例13Example 13
装置的高温湿热消毒。利用数控机床加工的方式将不锈钢材质制备实施例2中的活塞管体;用聚四氟乙烯棒制做可与管体密封良好的活塞推杆;将微孔膜与活塞管体以可拆卸连接的方式组装成活塞单元,微孔膜位于活塞管底。将组装好的活塞单元与活塞推杆在高温湿热条件(121.3℃,20分钟)下灭菌消毒,消毒完毕干燥冷却后即可用于细胞内递送试验。High temperature, humidity and heat disinfection of the device. The piston tube body in Example 2 is prepared from stainless steel by CNC machine tool processing; a PTFE rod is used to make a piston push rod that can be sealed with the tube body; the microporous membrane is detachably connected to the piston tube body Assembled into a piston unit in a way, the microporous membrane is located at the bottom of the piston tube. The assembled piston unit and piston push rod are sterilized under high temperature, humidity and heat conditions (121.3°C, 20 minutes). After the sterilization is completed, they can be used for intracellular delivery test after drying and cooling.
最后应说明的是:以上各实施例仅用以说明本公开的技术方案,而非对其限制;尽管参照前述各实施例对本公开进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本公开各实施例技术方案的范围。Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present disclosure, not to limit them; although the present disclosure has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand: It is still possible to modify the technical solutions described in the foregoing embodiments, or equivalently replace some or all of the technical features; these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the technical solutions of the embodiments of the present disclosure. range.
工业实用性Industrial applicability
本公开提供的装置能够将各种外源物质递送至真核细胞内。该递送过程不需要使用微流控和电场。并且本公开可以递送包括质粒DNA等较大的外源物质进入细胞核并表达编码蛋白质。本公开可以实现高通量地向真核细胞转移外源物质。The device provided by the present disclosure can deliver various foreign substances into eukaryotic cells. The delivery process does not require the use of microfluidics and electric fields. In addition, the present disclosure can deliver large foreign substances including plasmid DNA into the nucleus and express encoded proteins. The present disclosure can realize high-throughput transfer of foreign substances to eukaryotic cells.

Claims (22)

  1. 一种外源物质递送至真核细胞内的装置,其特征在于,所述装置包含挤出模块,所述挤出模块中设置分布有规则孔道的微孔膜,所述孔道的孔径小于所述真核细胞的直径;所述挤出模块还包括用于驱动真核细胞和外源物质同时通过孔道的压力单元。A device for delivering exogenous substances into eukaryotic cells, characterized in that the device comprises an extrusion module in which a microporous membrane with regular pores is arranged, and the pore diameter of the pore is smaller than the The diameter of the eukaryotic cell; the extrusion module also includes a pressure unit for driving the eukaryotic cell and the foreign substance through the pore at the same time.
  2. 根据权利要求1所述的装置,其特征在于,所述装置还包括温控模块,所述温控模块配置成通过与挤出模块接触以控制挤出模块和混悬液形式的真核细胞及外源物质的温度。The device according to claim 1, wherein the device further comprises a temperature control module configured to control the extrusion module and eukaryotic cells in the form of a suspension by contacting the extrusion module The temperature of the foreign material.
  3. 根据权利要求2所述的装置,其特征在于,所述温控模块包括流体循环控温单元或半导体制冷单元。The device according to claim 2, wherein the temperature control module comprises a fluid circulation temperature control unit or a semiconductor refrigeration unit.
  4. 根据权利要求2或3所述的装置,其特征在于,所述流体循环控温单元设置有和挤出模块接触的腔体,所述腔体配置成用于流体循环控温单元中的流体流通。The device according to claim 2 or 3, wherein the fluid circulation temperature control unit is provided with a cavity in contact with the extrusion module, and the cavity is configured for fluid circulation in the fluid circulation temperature control unit .
  5. 根据权利要求1-4中任一项所述的装置,其特征在于,所述压力单元是活塞单元,所述活塞单元配置成驱动混悬液形式的真核细胞及外源物质同时通过孔道。The device according to any one of claims 1 to 4, wherein the pressure unit is a piston unit, and the piston unit is configured to drive eukaryotic cells and exogenous substances in a suspension form through the pores at the same time.
  6. 根据权利要求5所述的装置,其特征在于,所述活塞单元配置成向细胞和外源物质施与正压力,以使细胞和外源物质通过所述孔道。The device according to claim 5, wherein the piston unit is configured to apply a positive pressure to the cells and the foreign substance, so that the cells and the foreign substance pass through the pores.
  7. 根据权利要求5或6所述的装置,其特征在于,所述活塞单元包括活塞管体和活塞推杆。The device according to claim 5 or 6, wherein the piston unit includes a piston tube and a piston push rod.
  8. 根据权利要求5-7中任一项所述的装置,其特征在于,所述活塞单元包括用于驱动活塞推杆的驱动单元。7. The device according to any one of claims 5-7, wherein the piston unit comprises a driving unit for driving a piston push rod.
  9. 根据权利要求8所述的装置,其特征在于,所述驱动单元包括手动或电机驱动单元。The device according to claim 8, wherein the drive unit comprises a manual or motor drive unit.
  10. 根据权利要求7-9所述的装置,其特征在于,所述微孔膜与所述活塞管体可拆卸连接。9. The device according to claims 7-9, wherein the microporous membrane is detachably connected to the piston tube body.
  11. 根据权利要求7-10中任一项所述的装置,其特征在于,所述活塞管体的材质包括金属材料、合金材料或除玻璃外的非金属材料。The device according to any one of claims 7-10, wherein the material of the piston tube body comprises a metal material, an alloy material or a non-metal material other than glass.
  12. 根据权利要求11所述的装置,其特征在于,所述除玻璃外的非金属材料包括高分子材料。The device according to claim 11, wherein the non-metallic material other than glass comprises a polymer material.
  13. 根据权利要求7-12中任一项所述的装置,其特征在于,所述活塞推杆的材质包括天然高分子材料或合成高分子材料。The device according to any one of claims 7-12, wherein the material of the piston push rod comprises a natural polymer material or a synthetic polymer material.
  14. 根据权利要求1所述的装置,其特征在于,所述装置还包括用于控制挤出模块的环境温度的温控模块;The device according to claim 1, wherein the device further comprises a temperature control module for controlling the ambient temperature of the extrusion module;
    优选地,所述温控模块通过与挤出模块接触以控制挤出模块的温度;Preferably, the temperature control module is in contact with the extrusion module to control the temperature of the extrusion module;
    优选地,所述温控模块包括流体循环控温单元或半导体制冷单元;Preferably, the temperature control module includes a fluid circulation temperature control unit or a semiconductor refrigeration unit;
    优选地,所述流体循环控温单元设置有和挤出模块接触的腔体,所述腔体用于流体循环控温单元中的流体流通。Preferably, the fluid circulation temperature control unit is provided with a cavity in contact with the extrusion module, and the cavity is used for fluid circulation in the fluid circulation temperature control unit.
  15. 根据权利要求1所述的装置,其特征在于,所述压力单元向细胞和外源物质施与正压力,以使细胞和外源物质通过所述孔道;The device according to claim 1, wherein the pressure unit applies a positive pressure to the cells and foreign substances, so that the cells and foreign substances pass through the pores;
    优选地,所述压力单元包括活塞单元;Preferably, the pressure unit includes a piston unit;
    优选地,所述活塞单元包括活塞管体和活塞推杆;Preferably, the piston unit includes a piston tube and a piston push rod;
    优选地,活塞单元包括用于驱动活塞推杆的驱动单元,所述驱动单元优选包括电机;Preferably, the piston unit includes a driving unit for driving the piston push rod, and the driving unit preferably includes a motor;
    优选地,所述微孔膜与所述挤出模块可拆卸连接;Preferably, the microporous membrane is detachably connected to the extrusion module;
    优选地,所述活塞管体的材质包括金属材料、合金材料或非金属材料;Preferably, the material of the piston tube body includes metallic material, alloy material or non-metallic material;
    优选地,所述金属材料包括铝或铜;Preferably, the metal material includes aluminum or copper;
    优选地,所述合金材料包括不锈钢或钛镁合金;Preferably, the alloy material includes stainless steel or titanium-magnesium alloy;
    优选地,所述非金属材料包括玻璃;Preferably, the non-metallic material includes glass;
    优选地,所述活塞推杆的材质包括天然高分子材料或合成高分子材料;Preferably, the material of the piston push rod includes natural polymer material or synthetic polymer material;
    优选地,所述天然高分子材料优选包括橡胶;Preferably, the natural polymer material preferably includes rubber;
    优选地,所述合成高分子材料优选包括聚酯类;Preferably, the synthetic polymer material preferably includes polyesters;
    优选地,所述合成高分子材料优选包括聚四氟乙烯和/或聚乙烯。Preferably, the synthetic polymer material preferably includes polytetrafluoroethylene and/or polyethylene.
  16. 根据权利要求1-15任一项所述的装置,其特征在于,所述微孔膜的材质包括金属或非金属;The device according to any one of claims 1-15, wherein the material of the microporous membrane comprises metal or non-metal;
    优选地,所述微孔膜的材质包括非金属;Preferably, the material of the microporous membrane includes non-metal;
    优选地,所述非金属包括聚合物、陶瓷或硅;优选包括聚合物;Preferably, the non-metal includes polymer, ceramic or silicon; preferably includes polymer;
    优选地,所述聚合物包括聚对苯二甲酸乙二醇酯、聚四氟乙烯、聚碳酸酯、聚酰亚胺、聚酰胺、醋酸纤维素、硝酸纤维素、聚乙烯、聚醚砜或聚四氟乙烯;Preferably, the polymer includes polyethylene terephthalate, polytetrafluoroethylene, polycarbonate, polyimide, polyamide, cellulose acetate, nitrocellulose, polyethylene, polyethersulfone or Polytetrafluoroethylene;
    优选地,所述聚合物包括聚对苯二甲酸乙二醇酯、聚酰亚胺或聚碳酸酯;Preferably, the polymer includes polyethylene terephthalate, polyimide or polycarbonate;
    优选地,所述规则的孔道采用蚀刻或打孔制备得到;Preferably, the regular holes are prepared by etching or perforating;
    优选地,所述打孔包括冲压打孔;Preferably, the punching includes punching and punching;
    优选地,所述蚀刻包括径迹蚀刻或光蚀刻;其中光蚀刻优选激光蚀刻;Preferably, the etching includes track etching or photo etching; wherein the photo etching is preferably laser etching;
    优选地,所述微孔膜使用径迹蚀刻制备得到。Preferably, the microporous membrane is prepared by track etching.
  17. 一种外源物质递送至真核细胞内的方法,其特征在于,所述方法包括:将包含真核细胞和外源物质的混悬体系经权利要求1-16任一项所述的装置挤出,以使外源物质递送至真核细胞内;A method for delivering exogenous substances into eukaryotic cells, wherein the method comprises: squeezing a suspension system containing eukaryotic cells and exogenous substances through the device of any one of claims 1-16 Out, so that foreign substances can be delivered into eukaryotic cells;
    优选地,所述递送包括将外源物质递送至真核细胞质内和/或递送至真核细胞核内。Preferably, the delivery includes the delivery of the foreign substance into the eukaryotic cytoplasm and/or the delivery into the eukaryotic nucleus.
  18. 根据权利要求17所述的方法,其特征在于,所述外源物质包括葡聚糖、DNA、RNA、蛋白质、核糖核蛋白复合体和纳米器件中的至少一种;The method according to claim 17, wherein the exogenous substance comprises at least one of dextran, DNA, RNA, protein, ribonucleoprotein complex and nanodevice;
    优选地,所述外源物质包括DNA、RNA、蛋白质和核糖核蛋白复合体中的至少一种;RNA优选包括mRNA、siRNA、miRNA或lncRNA;Preferably, the exogenous substance includes at least one of DNA, RNA, protein and ribonucleoprotein complex; RNA preferably includes mRNA, siRNA, miRNA or lncRNA;
    优选地,DNA包括生物来源的DNA或合成DNA;Preferably, DNA includes biologically derived DNA or synthetic DNA;
    优选地,所述生物来源的DNA包括质粒;Preferably, the DNA of biological origin includes a plasmid;
    优选地,RNA包括mRNA、siRNA、miRNA或lncRNA;Preferably, RNA includes mRNA, siRNA, miRNA or lncRNA;
    优选地,所述外源物质包含至少一种不能通过自由扩散跨越细胞核膜核孔复合体的物质;Preferably, the exogenous substance contains at least one substance that cannot cross the nuclear membrane nuclear pore complex by free diffusion;
    优选地,所述不能通过自由扩散跨越细胞核膜核孔复合体的物质包括葡聚糖,所述葡聚糖的分子量至少为41kDa,优选为70kDa~2MDa,更优选为2MDa的葡聚糖;Preferably, the substance that cannot cross the nuclear membrane nuclear pore complex by free diffusion includes dextran, the molecular weight of the dextran is at least 41kDa, preferably 70kDa-2MDa, more preferably 2MDa dextran;
    优选地,所述不能通过自由扩散跨越细胞核膜核孔复合体的物质包括DNA,所述DNA的分子量至少为1kbp。Preferably, the substance that cannot cross the nuclear membrane nuclear pore complex by free diffusion includes DNA, and the molecular weight of the DNA is at least 1 kbp.
  19. 根据权利要求17或18所述的方法,其特征在于,所述真核细胞来源于哺乳动物;优选地,所述哺乳动物优选包括人或鼠;The method according to claim 17 or 18, wherein the eukaryotic cells are derived from mammals; preferably, the mammals preferably include humans or mice;
    优选地,所述真核细胞包括原代细胞或细胞株;Preferably, the eukaryotic cells include primary cells or cell lines;
    优选地,所述原代细胞包括免疫细胞、肿瘤细胞或干细胞;Preferably, the primary cells include immune cells, tumor cells or stem cells;
    优选地,所述免疫细胞包括T细胞、B细胞、DC细胞、NK细胞、单核细胞、肥大细胞、嗜酸性粒细胞、嗜碱性粒细胞、嗜中性粒细胞或巨噬细胞;Preferably, the immune cells include T cells, B cells, DC cells, NK cells, monocytes, mast cells, eosinophils, basophils, neutrophils or macrophages;
    优选地,所述干细胞包括造血干细胞、间充质干细胞或皮肤干细胞;Preferably, the stem cells include hematopoietic stem cells, mesenchymal stem cells or skin stem cells;
    优选地,所述细胞包括人源的免疫细胞。Preferably, the cells include immune cells of human origin.
  20. 根据权利要求17-19任一项所述的方法,其特征在于,包含真核细胞和外源物质的混悬体系一次性经所述装置挤出;The method according to any one of claims 17-19, wherein a suspension system comprising eukaryotic cells and foreign substances is extruded through the device at one time;
    优选地,一次性经所述装置挤出的混悬体系的体积至少为0.5mL;Preferably, the volume of the suspension system extruded through the device at one time is at least 0.5 mL;
    优选地,一次性经所述装置挤出的混悬体系中的真核细胞数量至少为0.6×10 6个。 Preferably, the number of eukaryotic cells in the suspension system extruded through the device at one time is at least 0.6×10 6 .
  21. 根据权利要求17-20任一项所述的方法,其特征在于,所述方法还包括孵育挤出后的细胞和外源物质;The method according to any one of claims 17-20, wherein the method further comprises incubating the extruded cells and exogenous substances;
    优选地,在继续培养经过挤出的细胞前,分离混悬体系中的外源物质。Preferably, the exogenous substances in the suspension system are separated before continuing to culture the extruded cells.
  22. 权利要求1-16任一项所述的装置,或权利要求17-21任一项所述的外源物质递送至真核细胞内的方法在调控细胞功能中的应用;The application of the device according to any one of claims 1-16, or the method for delivering exogenous substances into eukaryotic cells according to any one of claims 17-21 in regulating cell functions;
    优选地,所述调控细胞功能包括短暂调控或持续调控;Preferably, the regulation of cell function includes transient regulation or continuous regulation;
    优选地,所述调控细胞功能包括下调或上调细胞中特定蛋白的表达;Preferably, the regulating cell function includes down-regulating or up-regulating the expression of a specific protein in the cell;
    优选地,下调细胞中特定蛋白的表达包括下调程序性死亡受体-1、T细胞受体或主要组织相容性复合体的表达;Preferably, down-regulating the expression of a specific protein in a cell includes down-regulating the expression of programmed death receptor-1, T cell receptor or major histocompatibility complex;
    优选地,所述调控细胞功能包括使细胞表达外源蛋白;Preferably, the regulation of cell functions includes allowing cells to express foreign proteins;
    优选地,所述外源蛋白包括嵌合抗原受体、识别特定抗原的T细胞受体和β球蛋白。Preferably, the foreign protein includes a chimeric antigen receptor, a T cell receptor that recognizes a specific antigen, and β globulin.
PCT/CN2020/099054 2019-07-01 2020-06-29 Device and method for delivering exogenous substances into eukaryotic cells and application thereof WO2021000844A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910585544.1 2019-07-01
CN201910585544.1A CN110272810A (en) 2019-07-01 2019-07-01 Allogenic material is delivered to device and method and its application in eukaryocyte

Publications (1)

Publication Number Publication Date
WO2021000844A1 true WO2021000844A1 (en) 2021-01-07

Family

ID=67963792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/099054 WO2021000844A1 (en) 2019-07-01 2020-06-29 Device and method for delivering exogenous substances into eukaryotic cells and application thereof

Country Status (2)

Country Link
CN (1) CN110272810A (en)
WO (1) WO2021000844A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12024483B2 (en) 2019-11-13 2024-07-02 Taizhou Chuangyuan Industrial Technology Co., Ltd Synthesis method of hydroxybenzylamine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210371881A1 (en) * 2020-05-26 2021-12-02 TransCytos, LLC Devices and methods for transfection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100203148A1 (en) * 2009-02-12 2010-08-12 University Of South Carolina Encapsulation and Controlled Release of Small Molecules for Intracellular Delivery Using Thermally Responsive Nanocapsules
WO2013059343A1 (en) * 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
CN205268753U (en) * 2015-12-03 2016-06-01 常州天地人和生物科技有限公司 Equivalent filter type syringe for injection
CN107441592A (en) * 2017-08-17 2017-12-08 青岛江河湖海创新技术研究院有限公司 One kind is medical can hot injection device
WO2018064387A1 (en) * 2016-09-28 2018-04-05 Novartis Ag Porous membrane-based macromolecule delivery system
CN108138118A (en) * 2015-09-04 2018-06-08 Sqz生物技术公司 By the Intracellular delivery for the biomolecule that tool hole surface mediates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107982548A (en) * 2012-02-07 2018-05-04 全球生物疗法有限公司 Compartmentation method of nucleic acid conveying and combinations thereof and application
JP6846345B2 (en) * 2014-11-14 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー Destruction and field delivery of compounds and compositions to cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100203148A1 (en) * 2009-02-12 2010-08-12 University Of South Carolina Encapsulation and Controlled Release of Small Molecules for Intracellular Delivery Using Thermally Responsive Nanocapsules
WO2013059343A1 (en) * 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
CN108138118A (en) * 2015-09-04 2018-06-08 Sqz生物技术公司 By the Intracellular delivery for the biomolecule that tool hole surface mediates
CN205268753U (en) * 2015-12-03 2016-06-01 常州天地人和生物科技有限公司 Equivalent filter type syringe for injection
WO2018064387A1 (en) * 2016-09-28 2018-04-05 Novartis Ag Porous membrane-based macromolecule delivery system
CN107441592A (en) * 2017-08-17 2017-12-08 青岛江河湖海创新技术研究院有限公司 One kind is medical can hot injection device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DING, XIAOYUN: "High-throughput Nuclear Delivery and Rapid Expression of DNA via Mechanical and Electrical Cell-Membrane Disruption", NAT.BIOMED.ENG., no. 1,, 18 September 2017 (2017-09-18), XP055565122, DOI: 20200910221630A *
TONER, MEHMET: "Suddenly squeezed and shocked A microfluidic device that integrates mechanical squeezing and electrical stimulation delivers DNA to the nucleus of cells at a rate of millions of cells per minute", NATURE BIOMEDICAL ENGINEERING, vol. 1,, 9 March 2017 (2017-03-09), XP055771649, DOI: 20200910222515A *
WILLIAMS A.R. ET AL.: "Filtroporation: A Simple, Reliable Technique for Transfection and Macromolecular Loading of Cells in Suspension", BIOTECHNOLOGY AND BIOENGINEERING, vol. 65, no. 3, 5 November 1999 (1999-11-05), XP055565397, DOI: 20200910230616 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12024483B2 (en) 2019-11-13 2024-07-02 Taizhou Chuangyuan Industrial Technology Co., Ltd Synthesis method of hydroxybenzylamine

Also Published As

Publication number Publication date
CN110272810A (en) 2019-09-24

Similar Documents

Publication Publication Date Title
US11377652B2 (en) Micro flow-through electroporation devices and methods of cell transfection
JP7046795B2 (en) Intracellular delivery of biomolecules mediated by surfaces with pores
Xie et al. Nanostraw–electroporation system for highly efficient intracellular delivery and transfection
US6589786B1 (en) Cell separation using electric fields
US20160298074A1 (en) Flow electroporation device
US20190275520A1 (en) Flow-through microfluidic methods and devices featuring membrane-perturbing surface interactions for intracellular delivery
WO2021000844A1 (en) Device and method for delivering exogenous substances into eukaryotic cells and application thereof
Wang et al. Semicontinuous flow electroporation chip for high-throughput transfection on mammalian cells
JP7313363B2 (en) Intracellular delivery and methods therefore
CN109679844A (en) A kind of flow electroporation device
US11999966B2 (en) Apparatuses and methods using nanostraws to deliver biologically relevant cargo into non-adherent cells
Jayasooriya et al. mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells
Selmeczi et al. Efficient large volume electroporation of dendritic cells through micrometer scale manipulation of flow in a disposable polymer chip
US20230114435A1 (en) Devices and methods for increasing throughput of flow-based electroporation systems
US20230109873A1 (en) Devices, methods, and systems for electroporation using controlled parameters
US20220347468A1 (en) Methods for electro-mechanical transfection
Tay et al. Research highlights: Manipulating cells inside and out
US20240173717A1 (en) Multistage device and method for intracellular delivery
TW202237858A (en) Precision drug screening for personalized cancer therapy
US20230105923A1 (en) A method and system for introducing one or more exogenous substances into an immune cell
EP2997125A1 (en) Method and device
JP2022540797A (en) Devices, systems and kits for electromechanical delivery and methods of their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20834329

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20834329

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/07/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20834329

Country of ref document: EP

Kind code of ref document: A1